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ABSTRACT OF THE DISSERTATION 
MULTIFUNCTIONAL NANOPARTICLES IN CANCER: IN VITRO 
CHARACTERIZATION, IN VIVO DISTRIBUTION, AND CELLULAR RESPONSE 
AFTER LASER-NIR DYE-INDUCED HEATING 
by 
Tingjun Lei 
Florida International University, 2013 
Miami, Florida 
Professor Anthony J. McGoron, Major Professor 
A novel biocompatible and biodegradable polymer, termed poly(Glycerol malate co-
dodecanedioate) (PGMD), was prepared by thermal condensation method and used for 
fabrication of nanoparticles (NPs). PGMD NPs were prepared using the single oil 
emulsion technique and loaded with an imaging/hyperthermia agent (IR820) and a 
chemotherapeutic agent (doxorubicin, DOX). The size of the void PGMD NPs, IR820-
PGMD NPs and DOX-IR820-PGMD NPs were approximately 90 nm, 110 nm, and 125 
nm respectively. An acidic environment (pH=5.0) induced higher DOX and IR820 
release compared to pH=7.4. DOX release was also enhanced by exposure to laser, which 
increased the temperature to 42°C. Cytotoxicity of DOX-IR820-PGMD NPs was 
comparable in MES-SA but was higher in Dx5 cells compared to free DOX plus IR820 
(p<0.05). The combination of hyperthermia (HT) and chemotherapy improved 
viii 
 
cytotoxicity in both cell lines. We also explored the cellular response after rapid, short-
term and low thermal dose (laser/Dye/NP) induced-heating, and compared it to slow, 
long-term and high thermal dose cell incubator heating by investigating the reactive 
oxygen species (ROS) level, hypoxia-inducible factor-1α (HIF-1α) and vascular 
endothelial growth factor (VEGF) expression. The cytotoxicity of IR820-PGMD NPs 
after laser/Dye/NP HT resulted in higher cancer cell killing compared to incubator HT. 
ROS level, HIF-1α and VEGF expression were elevated under incubator HT, while 
maintained at the baseline level under the laser/Dye/NP HT. In vivo mouse studies 
showed that NP formulation significantly improved the plasma half-life of IR820 after 
tail vein injection. Significant lower IR820 content was observed in kidney in DOX-
IR820-PGMD NP treatment as compared to free IR820 treatment in our biodistribution 
studies (p<0.05). In conclusion, both IR820-PGMD NPs and DOX-IR820-PGMD NPs 
were successfully developed and used for both imaging and therapeutic purposes. Rapid 
and short-term laser/Dye/NP HT, with a low thermal dose, did not up-regulate HIF-1α 
and VEGF expression, whereas slow and long-term incubator HT, with a high thermal 
dose, can enhance expression of both HIF-1α and VEGF.   
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CHAPTER 1: INTRODUCTION 
1.1.The cancer problem and current cancer therapy 
Cancer has become a serious problem for human society. Currently, it is the 1st and 2nd 
leading cause of death in developed and developing countries, respectively (1). Human 
cancer involves different and complicated molecular alterations in cells and its causes are 
very hard to define. Current clinical therapy for cancer includes chemotherapy, 
radiotherapy, surgery, and less commonly hyperthermia (HT) and gene therapy, among 
others. It has been shown that the combination of two or more therapies together, such as 
radiotherapy with chemotherapy, radiotherapy with HT, or chemotherapy with HT 
(chemo-thermotherapy), etc. can achieve better outcomes than do single therapies alone 
(2). Traditional diagnostic and therapy techniques have largely proven insufficient for 
successful medical management in cancer patients, since they are limited in specificity to 
tumor tissue, and too often possess very high toxicity to normal tissues (3, 4). Some 
therapies are referred to as “adjuvants”, which are treatments given in addition to the 
main or primary treatment and are intended as an enhancement to the primary therapy. 
Although there are many therapy methods available today, new methods using advanced 
technologies are still required for accurate and precise diagnosis, especially in tumor 
imaging and earlier detection. New strategies to lower or eliminate the side effects of 
cancer therapy to normal tissues also need to be developed. Among cancer therapies, 
chemotherapy has been widely used in clinical treatment since many of the anticancer 
drugs bind to DNA and impair DNA function in fast proliferating cells. However, most, 
if not all, of these drugs are limited by the fact that they lack specificity, which may result 
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in accumulation in normal tissue and exhibit below-therapeutic concentrations at target 
tumor tissues (4).   
1.2. Nanotechnology and its application in drug delivery 
The development of specific drug delivery approaches was first proposed in 1906, the so-
called “magic bullet” (5). The advantages of specific targeted delivery of 
chemotherapeutic drugs include reducing toxicity in healthy tissue to minimize side 
effects and at the same time to maximize the therapeutic outcome in tumors. Thus, the 
developing of optimal drug carriers to achieve targeted delivery has been a primary focus 
in drug delivery research over the past few decades. Cancer nanotechnology as an 
emerging new field is being considered for drug carrier applications. Nanotechnology 
involves multiple disciplines of chemistry, biology, medicine and engineering and is 
expected to offer many desired cancer therapeutic outcomes with respects to detection, 
analysis, and treatment (6, 7). Some successful examples include the use of natural and 
synthetic polymeric, metal, and semiconductor nanoparticles (NPs) (8-10), micelles (11), 
and liposomes (12, 13).  There are also several studies on medical applications. Hood et 
al. used polymeric NPs as gene carriers to target to tumor vasculatures (14) and 
Harisinghani et al. (15) used superparamagnetic iron oxide NPs to detect prostate cancer. 
Among these delivery systems, natural and synthetic polymeric microparticles/NPs and 
liposomal delivery systems are very important strategies for cancer drug delivery.  
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1.2.1. Particle delivery system 
Particles can be used for targeted delivery since they are able to protect the 
drugs/genes/bio-molecules from degradation and increase plasma circulation time (reduce 
plasma clearance). They are also capable of controlled release and can be tagged with 
ligands on the surface providing for specific targeting to corresponding receptors on the 
target cells. 
1.2.1.1. Liposomal formulation 
Liposomes are colloidal particles which are prepared by phospholipid molecules from 
either chemical synthesis or natural sources (16). The idea of using liposomes as drug 
carriers originated in the 1960s with the discovery that dry lipid films can form spherical 
enclosed vesicles after hydration (17). Thirty years after their discovery, investigation of 
the potential applications of liposomes on drug delivery intensified in the U.S. after the 
Food and Drug Administration (FDA) approved a series of therapeutics based on 
liposomes. The good biodegradability and biocompatibility of liposomes encouraged 
scientists to investigate their potential to reduce toxicity and enhance the efficacy of the 
drug carried in the liposomes. Currently, there are several liposomes and lipid-based 
products approved for clinical use in the U.S. (18). The surface charge of liposomes may 
be negative, neutral, or positive depending on the lipid head group composition, which 
may influence stability and biodistribution, as well as the uptake by targeted cells. To 
obtain desired pharmacokinetics of liposome encapsulated drugs for both in vitro and in 
vivo applications, it is necessary to design small liposomes (~100 nm diameter) to obtain 
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longer systemic circulation time and minimize reticuloendothelial system (RES) 
clearance. Researchers have been working on either passive or active targeting of 
liposomes, which includes attaching polyethyleneglycol (PEG), monoclonal antibodies 
(mAbs), growth factors, or other molecules on liposome surfaces (19). It is expected that 
the systemic resident time of liposomes and specificity to targeted tissues may improve 
after these surface decorations.   
1.2.1.2. Nanoparticles delivery systems 
Depending on their size, particles can be divided into 3 different categories:  
macroparticles (50-200 µm); microparticles (1-50 µm); NPs (1-1000 nm). Among these 
different sizes of particles, NPs are being studied intensively due to their small size and 
capability to escape RES uptake, to enter capillaries, and their ease of uptake by cells 
through endocytosis. Researchers have been focused on developing lipid, metallic, and 
polymeric NPs over the past decade. A plethora of the methods have been reported in the 
literature for the preparation of a large number of polymeric based NPs (20-23). Broadly, 
these methods can be divided into two categories. The first one is NPs synthesis from the 
polymerisation of monomers, where NPs are prepared by polymerisation of monomers or 
a mixture of monomers in an aqueous-organic phase or at the interphase of emulsion or 
microemulsion. The second category is synthesis from pre-formed polymers in which 
NPs are formed by various methods such as salting-out, double emulsion, emulsification-
diffusion and emulsification-solvent evaporation methods (24-27). There are mainly two 
different ways to obtain polymeric NPs: from naturally derived polymers or using 
synthetic polymers.  
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1.2.1.2.1. Naturally derived polymers include fibrin, collagen, chitosan, gelatin, and 
starch or cellulose derivatives, among others (28). The advantages of natural polymers 
are that they have very good biocompatibility that may positively support cell adhesion 
and function, and most of them are biodegradable and usually show low toxicity. 
However, naturally derived polymers also have disadvantages, such as potential 
immunogenicity, lesser control over their mechanical properties, inconsistency between 
batches, risk of animal virus transmission, and high cost due to limited supply (29).  
1.2.1.2.2. Synthetic polymers include polyesters such as poly(lactic acid) (PLA), 
poly(glycolic acid) and the copolymer of lactic and glycolic acid, i.e. poly(lactide-co-
glycolide) (PLGA) have been extensively explored. Other common classes of polymers 
used to encapsulate drugs in colloidal systems include poly(amino acids), 
poly(orthoester)s, and polyanhydrides etc. (30-33). The advantages of using synthetic 
biodegradable polymers are: (a) good biocompatibility  and minimize the risk of 
biological pathogens or contaminants. (b) controllable biodegradation and release profiles 
since the degradation rate can be tailored to meet the requirements from several weeks to 
several years (e.g. by altering LA/GA ratio in PLGA copolymers). (c) can be designed 
with chemical functional groups that can induce cell growth. (d) specific synthesis 
methods can be chosen to obtain compatibility with the specific drugs to be delivered and 
with high drug loading efficiency. (e) inexpensive and reproducible in large scale 
production with controlled properties.  
Synthetic polymers also have disadvantages:  (a) release byproducts which could 
influence cell growth, for instance, acidic degradation products (e.g. lactic acid and 
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glycolic acid) can be released in the case of PLGA; (b) have poor ability to undergo 
processing and can lose of mechanical properties during degradation; (c) chemical 
synthesis may include toxic substances. 
Among the various polymers that can be used to formulate NPs, PLGA is one of the most 
important. It is a co-polymer of lactic acid and glycolic acid and has been studied 
intensively since its approval by the FDA for various medical applications. Currently, 
there are many studies incorporating therapeutic agents into PLGA NPs and used for 
gene/drug/biomolecules delivery, including our lab (20, 34, 35).  
PLGA can encapsulate hydrophilic and/or hydrophobic drugs. Hydrophobic species, such 
as paclitaxel, doxorubicin (DOX), or quercetin, can be protected by PLGA from 
premature degradation so that they can reach their target sites (36). The degradation of 
PLGA is usually through hydrolysis of the ester linkages (37). The byproducts after 
degradation include lactic acid and glycolic acid, which can be naturally removed from 
the body. Extensive studies of PLGA NPs incorporating anticancer drugs have been 
reported, including entrapping DOX, paclitaxel, dexamethasone etc. (38-40). The criteria 
for using NPs in drug delivery includes: (a) particles have to be compatible with drugs 
and achieve high drug loading efficiency; (b) particles have to be stable and have a 
controllable drug release profile; (c) biodegradation products have to be safe; (d) 
synthesis process has to be inexpensive and reproducible. 
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1.2.2. Targeted delivery of NPs 
1.2.2.1. Passive targeting 
NPs can efficiently reach tumor sites through the enhanced permeability and retention 
(EPR) effect arising from the lack of an effective lymphatic drainage system as well as 
the presence of vascular endothelial growth factor (VEGF) promoting angiogenesis 
which leads to leaky micro-vessels. The endothelial cells in tumor vasculature have loose 
interconnections and focal intercellular openings. These breaks in the endothelial cell 
lining range in size between 100 to 780 nm, and NPs carrying the required therapeutic 
agent can easily extravasate these openings (41, 42), which results in increased 
accumulation of drugs in tumor sites and lower toxicity in other healthy tissues without 
these vascular properties. The accumulation of NPs in tumor tissue using leaky 
vasculature is called passive targeting. Another advantage for using NPs as drug carriers 
is they are able to overcome multidrug resistance (MDR) by bypassing drug exporter 
pumps (35). MDR may develop in cancer cells due to the cells overexpressing p-
glycoprotein (P-gp) which pumps out the drugs and compromises the chemotherapy 
effect (43). 
1.2.2.2. Active targeting 
The EPR effect facilitates drug escape from the plasma into the tumor interstitium. More 
specific targeting to tumor cells to obtain even higher treatment efficacy can be achieved 
by decorating the surface of NPs with appropriate tagging moieties; for instance, ligands, 
antibodies, or biomarkers to selectively interact with receptors on the tumor cell 
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membrane (18, 44). The tagging of ligands on NPs aiming at particular receptors on 
target tissues is called active targeting. There are many ligands that can be used for this 
purpose, such as peptides, carbohydrates, and monoclonal antibodies (mAbs). Extensive 
research has been focused on mAbs-based cancer therapies which have shown success 
towards targeting cancer (45, 46). Initially, mAbs were conjugated directly to the drugs. 
However, this method was not very successful since it often changed the function and 
bioactivity of the drug during the conjugation process and affected the pharmacokinetics 
of the drugs (47, 48). Our lab has shown that conjugating human epidermal receptor 
(HER-2) to DOX-loaded PLGA NPs can increase the cellular uptake and cytotoxicity in 
the HER-2 receptor overexpressed human ovarian cancer cell line SKOV-3, but not in 
negative HER-2 cancer cell lines such as human uterine cancer lines MES-SA and MES-
SA/Dx5 (Dx5) (35). Thus, conjugating specific antibodies on NPs to target tumor cells 
seems to be a promising approach to specific drug delivery.  
1.2.3. The development of multifunctional NPs 
NPs can possess various functional groups on their surface which allows conjugation to 
multiple agents for improved diagnostics and chemotherapeutics. The idea of the 
development of multifunctional NPs as a platform for drug delivery has been emerging in 
recent years. One important advantage of using NPs as a platform for drug delivery is that 
they can incorporate an imaging agent for imaging tumors simultaneously with delivering 
chemotherapeutic drugs. Traditional in vivo imaging probes include positron emission 
tomography (PET), single photon emission computed tomography (SPECT), gadolinium 
compounds in magnetic resonance imaging (MRI). In comparison, the recent 
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development of nano-range molecular imaging probes, such as targeted quantum dots, 
near-infrared imaging agent encapsulated NPs and other bioengineering NPs provides 
several unique features. Their optical and electronic properties could be modified by 
changing the size of the particle, therapeutic agents (e.g. anticancer drugs) can be 
incorporated into the nanovehicles, and NPs can preferentially accumulate in tumor sites 
via the EPR effect. 
Optical imaging has high temporal resolution, and the imaging system is usually smaller 
and inexpensive as compared to the more traditional imaging techniques, such as 
computed tomography (CT), PET/SPECT, MRI etc. However, its clinical application has 
been limited by low depth penetration since visible light is highly absorbed and scattered 
by human tissue. In this respect, near-infrared imaging dyes (wavelength 700-900 nm) 
are promising agents for in vivo optical imaging because light within those wavelengths 
has minimal absorption by DNA and water, which improves tissue penetration (49, 50). 
Therefore, among a wide range of optical imaging agents, NIR dyes have been studied 
extensively for in vivo applications, but not dyes that absorb in the visible range due to 
the reasons mentioned before. Some of the NIR dyes can not only be used as imaging 
agents but can also act as heat generators due to their unique photothermal properties. 
Compounds such as cyanine dyes, phthalocyanine and rhodamine derivatives possess this 
quality (51-53). One of the most important NIR dyes is indocyanine green (ICG), since it 
is FDA-approved for some medical applications and has been used extensively clinically 
with a very good toxicity profile. In the past few decades, it has also been studied for its 
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potential use in photodynamic therapy, photothermal therapy and optical imaging (54-
56).  
Hyperthermia (HT) (also called thermal therapy, thermotherapy) is the application of heat 
(usually 41°C~45°C) to cancer cells. In some cases, much higher temperature are used to 
induce tumor ablation (60°C~80°C for 2~10 seconds), which result in irreversible 
destruction of the tumor cells (57). The mechanism of HT is of artificially elevating the 
temperature of the tissue with the aim of achieving therapeutic benefits and cancer cell 
killing by damaging proteins and structures inside cancer cells. HT is frequently used 
together with chemotherapy or radiotherapy to achieve synergistic effects, which can 
often result in higher cancer therapy efficacy than radiotherapy or chemotherapy alone.  
There are many successful examples in either phase II or phase III clinical trials for 
combining HT with radiotherapy, or HT with chemotherapy (58-62). There are also many 
other research efforts on NPs application to cancer therapy, one of which is by Park’s 
group (63). In their study, DOX-loaded PLGA-Au H-S NPs were fabricated and they 
showed that the simultaneous delivery of heat and drugs to tumor sites resulted in 
improved cytotoxicity to cancer cells, inhibiting tumor growth and ultimately destroying 
the tumor. Currently, gold NPs are being tested for their potential use in photothermal 
therapy in phase I human clinical trials (64). In addition to gold NPs, superparamagnetic 
iron oxide NPs are also under clinical investigation for the application of HT (65-67). 
One of the disadvantages of using gold NPs is they are not biodegradable. As mentioned 
above, ICG has also been studied intensively due to its good biocompatibility, 
biodegradability, and the ability to produce NIR range fluorescence light and heat after 
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excitation by a laser at the appropriate wavelength. One of the challenges for using ICG 
is its poor stability in aqueous solution and short plasma residence time (68). Scientists 
have been working on encapsulating ICG into NPs, such as PLGA NPs, to increase its 
stability and extend its plasma circulation time in vivo (69, 70).  
 
1.3. Novel polymeric NPs poly(glycerol-dodecanoate) (PGD)  
As mentioned before, increasing attention has been paid to synthetic polymers for 
applications in medicine and surgery over the last decades. Nevertheless, very few 
polymers have successfully entered into clinical trials. The chemistry involved in the 
synthesis of functional monomers is most often tedious and complex, whereas the 
subsequent polymerization is difficult to control. Out of these polymer-based agents, 
polyester based NPs in particular, also have good shelf life, suitable physicochemical 
properties, and well-characterized degradation products. However, their applications are 
potentially limited due to their inherent toxicity. Therefore, there is still a need to explore 
novel biodegradable polyesters in order to overcome these disadvantages and develop 
clinically translatable drug delivery vehicles.  
Migneco and Huang reported the synthesis of a novel polyester from glycerol and 
dodecanedioic (DDA) for biomedical applications, which maintains good mechanical and 
biological properties during degradation (71). This novel polyester poly(glycerol-
dodecanoate) (PGD) was formed mainly through ester bonds and its degradation is 
through the hydrolysis mechanism. The biodegradation products glycerol and DDA are 
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both biodegradable and biocompatible (72, 73). Synthesis of the PGD polymer was by 
mixing of glycerol and DDA in 1:1 molar ratio and heating at 120°C for 4~5 days. Cell 
growth studies revealed that PGD-treated plates initially show slower human fibroblast 
cell growth compared to controls, but at approximately day 18 cell growth in these plates 
had reached the same level as for control cell culture plates (71). It seems that this 
polymer is a good candidate for use in drug delivery thanks to its good biodegradability 
(mainly through surface erosion), biocompatibility, solubility in polar solvents (e.g. 
ethanol, acetonitrile), and ease and low cost of synthesis. 
1.4. DOX used as chemotherapeutic agent  
Chemotherapy is very often used as a first line therapy for cancer management. DOX and 
daunorubicin are anthracycline antibiotics which are both often used in human cancer 
chemotherapy. The anthracycline effectively kills cancer cells by intercalating to nuclear 
DNA and inhibiting topoisomerase II, leading to cell death (74, 75). However, its use has 
been limited by toxicity to normal tissues, and because of its lack of tissue or organ 
specificity. The main disadvantage of DOX is that it induces irreversible cardiotoxicity, 
presumably by localizing in the mitochondria of cardiomyocytes (76). Additionally, 
cancer cells can develop multidrug resistance (MDR) through the overexpression of P-gp. 
This results in anthracycline drugs being pumped out of the cells, with the subsequent 
reduction in therapeutic effect. Scientists are working on incorporating DOX into NPs to 
overcome MDR and achieve specific targeting to tumor cells. Several groups have 
incorporated DOX into PLGA NPs (38, 77, 78). In our lab, we have successfully 
encapsulated DOX into PLGA NPs that are able to bypass MDR and obtain higher 
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cellular uptake and cytotoxicity in P-gp overexpressing MES-SA/Dx5 cells compared to 
the free form of DOX (35). We further improved the cytotoxicity and cellular uptake of 
DOX to SKOV-3 by tagging HER-2 antibody on DOX-loaded PLGA NPs.  
 
 
1.5. IR820 used as imaging and photothermal agent 
As mentioned above, indocyanine green (ICG) has been studied intensively since it is an 
FDA-approved NIR dye. ICG (Ex: 785nm, Em: 830nm) can generate NIR range 
fluorescence light after being excited by a laser. Compared to visible light, absorption by 
human tissue is markedly reduced for NIR light, thus making it appropriate to be used for 
in vivo imaging. In our previous work, we have investigated the commercially available 
cyanine dye IR820, which could be considered as the alternative to ICG because of 
similar optical and thermal properties (79). A recent study by Massoti et al. conjugated 
IR820 to polyethylenimine (PEI) for in vivo imaging and DNA delivery (80).  
Our study showed the fluorescence quantum yield of IR820 to be lower than that of ICG. 
However, IR820 has a non-concentration dependent and more predictable absorption 
peak as compared to ICG (79). Also, IR820 is more stable than ICG in aqueous solution 
with degradation half-times about double those of ICG. The ability of IR820 to produce 
heat after exposure to laser is somewhat less compared to ICG. Our work showed that 5 
µM IR820 in cell culture media is able to elevate the temperature from 37°C to 42°C 
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during exposure to 3 min laser with power as 1,440 J/cm2, while 5 µM ICG can cause 
temperature change from 37°C to 45°C (79). Although a difference exists, the 
temperature increase obtained with the use of IR820 is within the range needed for 
selective cancer cell HT, and our study showed that IR820 can be used to significantly 
inhibit cancer cell growth upon laser exposure in a manner comparable to ICG. In vivo 
studies showed that the fluorescent signal from IR820 can be detected for longer periods 
than that of ICG (79). The fluorescence signal of IR820 was observed to be stronger than 
ICG in both mice and rats 24h after tail vein injection. Rat and mice organ images and 
dye content studies in specific organs, measured by homogenizing and extracting the dye, 
also showed that IR820 localized to liver, lungs and kidney, and demonstrated stronger 
fluorescent signals than ICG in those organs. In sum, IR820 seems to be a good 
alternative to ICG because of the characteristics mentioned above.  
1.6. Drug release mechanisms in nanoparticles 
Drug release from NPs depends upon many factors, such as polymer composition and 
morphology, the size and density of the NPs, as well as the physicochemical properties of 
the drugs, etc.  Generally, the investigation of drug release rate involves: (a) the solubility 
of incorporated drug; (b) desorption of the surface bound/adsorbed drug; (c) drug 
diffusion through the polymeric NPs matrix; and (d) polymeric NPs matrix 
erosion/degradation. Thus, the drug release process is governed by drug solubility, 
diffusion and biodegradation of the NPs matrix. If the drug weakly binds or adsorbs to 
the surface of the polymer, it may instantaneously dissolve into the releasing solvent, 
resulting in an initial “burst” release (81). Diffusion-governed release means that the drug 
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is released from the NPs core across the polymer matrix and involves the following steps: 
1. penetration of water to NPs; 2. swelling of NPs and 3. drug release from the swollen 
NPs matrix. Moreover, in vitro release of the drug can be affected by the solvent pH, 
ambient temperature, and the ionic interaction between drug and polymers (82, 83).  
Polymer erosion can largely affect drug release from the polymer membrane. Depending 
upon the different polymer materials and size, degradation can take place through bulk 
erosion or surface erosion. Either one can result in loss of mass from polymer matrices, 
swelling of polymers, and changes in polymer morphology and molecular weight, etc. 
(84). There are many factors which could influence degradation rate, including 
composition of copolymer (85), autocatalysis with acidic degradation products of the 
polymer (86), interactions between the polymer and the encapsulated drug (87), etc. 
Burkersroda et al. (88) developed a theoretical model to determine whether polymer 
erosion occurs through bulk erosion or surface erosion mechanisms. Their model studied 
the relationship between the degradation rate constant of polymer functional groups λ and 
water diffusivity D, and investigated a parameter called critical device dimension 
“Lcritical”. The increase ratio of λ/D, or an increase of L can lead to changes in erosion 
mechanisms. L represents the chemical structure dimension of a polymer matrix and if 
the polymer matrix dimension is smaller than Lcritical, it will undergo bulk erosion. On the 
other hand, if the polymer matrix is larger than Lcritical, it will undergo surface erosion.  
1.7.Introduction of hypoxia-inducible factor-1 (HIF-1) 
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Hypoxia is often present in the center of solid tumors due to poorly formed vasculature 
resulting in low oxygen supply, which could significantly compromise the effect of 
chemotherapy and radiotherapy (89-92). It is reported that hypoxia-inducible factor-1 
(HIF-1), which includes α and β subunits, could circumvent the anticancer drug effect by 
not only escaping drug-induced apoptosis (93, 94), but also through non-apoptotic 
mechanisms, such as reducing drug-induced senescence in cancer cells (95). 
Radiotherapy could also be affected since oxygen can bind to unpaired electrons and free 
radicals that otherwise would damage DNA (90, 96). Therefore, effective radiotherapy 
depends on an adequate availability of oxygen. The inadequate oxygen supply could also 
result in cancer cell adaptation and lead to expression of various genes in cancer cells, 
including VEGF, and pyruvate dehydrogenase kinase 1 (PDK1), which are 
transcriptionally regulated by HIF-1 (94, 97).  
Given the importance of HIF-1, studies of the effect of HT on this protein are very 
relevant for therapeutic HT applications in cancer. Moon et al. reported that HIF-1 can be 
up-regulated by mild HT and lead to the expression of VEGF both in vitro and in vivo, 
and the increase of VEGF can lead to the promotion of tumor perfusion and 
vascularization (98). The detailed molecular mechanism of HT induced HIF-1 expression 
was described in Moon’s paper as follows: HT first activates the ERK pathway and 
causes an increase of the mRNA expression of NOX1, which promotes NADPH oxidase 
and generate reactive oxygen species (ROS)  to up-regulate HIF-1α expression. The study 
of Goyal et al. and Chandel et al. also demonstrated that the level of one type of ROS, 
hydrogen peroxide (H2O2), was increased in cells after NOX1 transfection (99), 
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highlighting the importance of H2O2 in HIF-1 activation in cells (100). A corroborating 
report by Katschinski’s group also described that heat can stabilize the unphosphorylated 
form of HIF-1α and up-regulate HIF-1α expression (101).  
ROS was also reported to play a role in the induction of Heat Shock Factor 1 (HSF1) and 
mRNA accumulation for HSP70, which belongs to the heat shock protein family (102). 
HSP70 can minimize the effect of heat on cells during heat exposure by up-regulating 
thermotolerance. This response would compromise the efficacy of HT (103, 104). It has 
also been reported by Madamanchi’s group that H2O2 can up-regulate HSP70 protein 
levels through the activation of the HSP70 promoter by binding of signal transducers and 
activators of transcription (STATs) to the promoters in vascular smooth muscle cells 
(VSMCs) (105). This group exposed VSMCs to H2O2 and found that the cytoplasmic 
janus tyrosine kinase 2 (JAK2)/STAT pathway can up-regulate HSP70 and minimize 
oxidative stress effects on the cells.  
Tang’s study investigated the effect of HT on cancer cells in a thermal dose dependent 
manner (106). His study showed that HSP70 was not activated by ICG-induced rapid 
heating after exposure to laser, and the thermal protective mechanism to cells was not 
initiated. The HSP70 activity after rapid, short-term and low thermal dose laser/ICG 
heating was low as compared to the increase expression of HSP70 under slow, long-term 
and high thermal dose heat accumulation using a cell culture incubator. ICG has been 
known to generate singlet oxygens after photoactivation, and Fickweiler et al. suggested 
that the cell killing effect of ICG after laser irradiation was mainly due to photodynamic 
effect and not the photothermal effect (51). Others have reported that the phothodynamic 
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effect would be dominant at low laser densities and high concentrations of ICG, whereas 
the photothermal effect would be dominant at higher laser energies (up to 20 W/cm2) and 
lower ICG concentrations (54). This is consistent with the notion that the activation of 
HSP70 was minimized in a rapid heating modality as described by Tang et al. (106). 
As mentioned before, ROS can activate the expression of HSP70. The low expression of 
HSP70 during rapid-rate heating could possibly mean the abolishment of ROS 
generation, or abolishment of ROS-induced expression of HSP70. Most of the papers 
proposing that HT can up-regulate ROS expression and elevate HIF-1 expression and P-
gp expression are based on the usage of slower, long-term HT with high thermal dose. It 
would be important to investigate if rapid and short-term laser/Dye/NP-induced HT, with 
a lower thermal dose, could result in ROS generation and trigger overexpression of HIF-1 
and VEGF. 
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CHAPTER 2: STATEMENTS AND SPECIFIC AIMS 
2.1.Statement of purpose 
Due to the unique and advantageous properties of PGD described above, it may be good 
candidates for use as a drug delivery vehicle. However, PGD has a low glass transition 
temperature (Tg=~32°C), which creates challenges in achieving controlled release of 
encapsulated agents. In addition, PGD is hydrophobic, which is not ideal in nanoparticle 
formulations for drug delivery purposes. In order to overcome these issues, we modified 
PGD polymers by adding malic acid and adjusting the ratio of malic acid to DDA during 
the PGD polymer synthesis process in order to adjust the hydrophilicity/hydrophobicity 
and have a controllable Tg. The formulation technique does not involve toxic chlorinated 
solvents, unlike the formulation of PLGA NPs, and the characteristics of PGMD NPs can 
be modified by modulating polymer composition, which provides versatility similar to 
that of PLGA. Specifically, the glass transition temperature (Tg) and hydrophilicity of 
PGMD NPs can be adjusted by changing the ratio of malic acid to DDA during the 
PGMD polymer synthesis process. These properties of PGMD polymer make it a good 
candidate for drug delivery applications. With the controllable Tg, we could easily 
manage the release profile, and the PGMD NPs can be used for incorporation of 
hydrophobic drugs or protein/DNA by adjusting PGMD polymer hydrophilicity. In 
addition, PGMD has natural byproducts, such as glycerol, malic acid and DDA, meaning 
that it is biocompatible and biodegradable. Following the synthesis of PGMD polymers, 
PGMD NPs were also successfully developed. The synthesis of PGMD NPs is easy and 
reproducible, and we can prepare uniform PGMD NPs with particles size between 100 to 
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150 nm for efficient drug delivery. Our goal is to use these PGMD NPs to incorporate the 
anticancer agent DOX and the imaging and photothermal agent IR820 for delivery to 
tumors.  
Therefore, the purpose of this study was to explore the efficacy of IR820-PGMD NPs and 
DOX-IR820-PGMD NPs for cancer therapy with in vitro and in vivo assessment, and lay 
the foundations for future development of targeted delivery approaches. IR820-PGMD 
NP and DOX-IR820-PGMD NP cytotoxicity in cancer cells were first studied and 
compared to free IR820 or free DOX plus free IR820 in MDR cancer cell lines (Dx5) and 
non-MDR cancer cell lines (MES-SA). Our previous studies showed that a higher cancer 
cell killing effect can be obtained if HT is applied with chemotherapy than by 
chemotherapy alone (55). However, in that study drug-loaded NPs were not used to 
deliver the HT. Based on those results, it is expected that both IR820-PGMD NPs and 
DOX-IR820-PGMD NPs would cause significant cancer cell killing after exposure to 
laser compared to the no-laser treated group due to the application of HT. Moreover, both 
NP formulations should be more toxic than free IR820, or free IR820 plus DOX) 
treatment in Dx5 cells due to NPs can overcome P-gp effect and result in higher cellular 
uptake and cytotoxicity to Dx5 than unencapsulated DOX and IR820. In addition, these 
particles also have the potential for targeting.  
The expression of ROS, HIF-1 and VEGF after exposure to a faster and shorter-term 
heating modality with lower thermal dose (laser/Dye/NP HT) were studied and compared 
to a slower and longer-term heating system with higher thermal dose (incubator HT). In 
the end, the biodistribution and pharmacokinetics studies were performed using both NP 
21 
 
formulations and the results were compared to free IR820 and DOX. This basic 
understanding can serve as a foundation for the ultimate achievement of targeted 
chemotherapy-HT NPs mediated cancer therapy. 
Most researchers have used Au or ICG as near-infrared imaging and HT agent for highly-
localized HT. Our group was the first to explore the potential use of IR820 or IR820 
conjugates as HT agent (79, 107, 108). Several groups, including ours, also analyzed the 
potential use of IR820 for imaging (79, 80, 109). To our knowledge, this is the first study 
to combine DOX and IR820 together and analyze their toxicity to cancer cells and the 
potential of IR820 as an imaging/HT agent after laser irradiation in newly developed 
PGMD NPs.  
In this study, we investigated multifunctional NP applications in cancer therapy and 
measured the cellular response after laser/Dye/NP-induced HT and incubator-induced 
HT. The slow but longer-term heating, as discussed before, would induce production of 
ROS and activate expression of HIF-1 and VEGF. Tumor angiogenesis occurs partly 
through activation of expression of VEGF, which is partially regulated by HIF-1. 
Additionally, HIF-1 is partially responsible for tumor reoxygenation and decreased tumor 
oxygen consumption, which would be important for radiotherapy. Thus, I believe the 
study of ROS, HIF-1, and VEGF expression after laser-induced HT is very important in 
order to explore cancer cell responses in fast-induced HT versus more traditional more 
slowly-induced HT. In this respect, this research is novel and important being the first to 
test the laser/Dye/NP and DOX-laser/Dye/NP cancer cell killing/growth inhibition effect 
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in vitro with and without laser exposure, and then to analyze the laser-induced rapid 
heating effect on ROS, HIF-1 and VEGF expression.   
For this purpose, in vitro cell culture experiments were conducted on the MDR human 
uterine sarcoma cancer cell line Dx5 and its non-MDR parent cell line MES-SA. Since 
the purpose is to establish the efficacy of the proposed treatment modality on cancer 
cells, normal cell lines are not included.  
In the end, we are also interested in performing in vivo pharmacokinetics and 
biodistribution studies. The purpose of in vivo studies is to compliment the in vitro 
studies, which provide valuable but limited information since the in vitro model cannot 
predict and represent the complexity of a living system. Animal models are often used to 
study a molecular or agent based on the positive in vitro experimental results. We want to 
explore the potential application of IR820-PGMD NPs/DOX-IR820-PGMD NPs for in 
vivo optical imaging, and identify the difference between nanoformulations and free 
drug/dye to see if the NPs can protect the encapsulated agents and result in different 
biodistribution and pharmacokinetics result from free drug/dye. In the present study the 
in vivo cancer therapy effects of the NP formulations were not tested however. 
Therefore, it is hypothesized that the PGMD NPs will be thermal and pH sensitive, thus a 
control release of DOX and IR820 will be achieved. The IR820-PGMD NPs and DOX-
IR820-PGMD NPs will achieve higher cellular uptake and cytotoxicity in MDR cancer 
cell lines as compared to free IR820 plus DOX. Also, chemotherapy and HT, when 
applied together in NP formulations with the HT induced by exposure to laser and NIR 
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absorbing dye, will induce higher cytotoxicity to cancer cells than chemotherapy alone in 
both non-MDR and MDR cell lines. In addition, the study will show that the NP 
formulation can protect the incorporated agents (DOX and IR820) and prolong their 
plasma half-lives, thus widening the diagnostic and therapeutic window. The slow and 
longer-term incubator HT, even at a higher thermal dose, does not result in greater cancer 
cell killing compared to laser HT. Moreover, incubator HT activates the ROS production 
and results in promotion of HIF-1 and VEGF expression. On the other hand, this study 
will demonstrate that the combination of HT and chemotherapy in NP delivery form 
induces a highly-localized and rapid heat accumulation after exposure to laser, with a 
lower thermal dose, but will not activate ROS production and enhance HIF-1 and VEGF 
expression, and will result in higher cancer cell killing than in the incubator HT. We 
believe the study of ROS, HIF-1 and VEGF expression in cancer cells after laser 
exposure is very important with respect to addressing the effect of different heating rates 
and thermal doses to cancer cells. We used incubator–induced HT to mimic whole-body 
HT, and the comparison between incubator HT and laser/Dye/NP HT may provide 
important information on the effects of different modalities of HT used in cancer therapy. 
In the end, I believe this study will provide an extension to the current knowledge of 
thermo-chemotherapy delivery in NP form, and will bring significant impact to the 
application of nanotechnology on cancer therapy.   
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2.2. Specific aims 
Aim 1, incorporation of IR820 and DOX into void PGMD NPs and characterization of 
IR820-PGMD NPs and DOX-IR820-PGMD NPs, including Fourier Transform InfraRed 
(FTIR) spectroscopy, Scanning Electron Microscopy (SEM), Dynamic Light Scattering 
(DLS) measurements, drug loading efficiency and release kinetics studies in different pH 
buffer and with exposing NPs to laser. Cell culture experiments were conducted for 
studying  IR820-PGMD NPs and DOX-IR820-PGMD NPs in both MES-SA and Dx5, 
including cellular uptake of NPs, NP subcellular localization, NP intracellular fate in the 
cytoplasm and their cytotoxicity.  
Aim 2, determine the production of ROS after laser/Dye/NP-induced HT and compare 
the results to incubator-induced HT. Then, HIF-1 and VEGF expression were 
investigated following ROS study. To accomplish this aim, IR820-PGMD NPs were used 
in an established laser induced rapid heating system to investigate the heating rate and 
thermal dose effect to the expression of ROS, HIF-1 and VEGF within cells. These 
results were compared to an incubator HT system, which is used to mimic the traditional 
whole body HT. The thermal dose of laser/Dye/NP HT and incubator HT was calculated 
by a cumulative equivalent minutes at 43 degree Celsius (CEM43) mathematical model.  
Aim 3, pharmacokinetics and biodistribution studies were done in mice. Mouse model 
was chosen due to their low cost and ease of handling. In addition, the mouse model had 
been well established for preclinical drug testing to determine their pharmacokinetic 
behavior and safety before use in humans. Therefore, mice were used to study the 
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biodistribution and pharmacokinetics of IR820-PGMD NPs/DOX-IR820-PGMD NPs, 
and the results compared to free IR820 and free DOX.  
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CHAPTER 3: METHODOLOGY  
3.1.The fulfillment of Specific Aim 1 
3.1.1. Preparation and characterization of PGMD polymer, void PGMD NPs, IR820-
PGMD NPs and DOX-IR820- PGMD NPs 
Doxorubicin hydrochloride (DOX-HCl; MW 579.95) was purchased from Waterstone 
Technology (Waterstone Technology, CA). Malic acid, 1, 12-Dodecanedioic acid (DDA), 
dimethylsulfoxide (DMSO>99.9%, reagent grade), pluronic F-127, micro bicinchonic 
acid (BCA) protein assay kits, Dulbecco’s phosphate-buffered saline (DPBS), phosphate 
buffered saline (PBS), IR820, penicillin–streptomycin solution, tetrahydrofuran (THF) 
and trypsin-EDTA were purchased from Sigma-Aldrich (Sigma, Louis). PGMD polymers 
were prepared following Mingueo’s paper with the modification of adding malic acid. 
Briefly, glycerol (MP Biomedical, LLC, Solon OH) and a combination of DDA and 
malic acid in 1:1 molar ratio was mixed and heated up to 120°C for 48 hours. The molar 
ratio of DDA to malic acid was 7:3. After that, the mixture was placed under vacuum and 
continuous stirring for 24 hours. The synthesis of void PGMD NPs, IR820-PGMD NPs 
and DOX-IR820-PGMD NPs were performed using the oil-in-water emulsification 
solvent evaporation method. Briefly, approximately 2 mg DOX-HCL and 2 mg IR820 
were measured and added to 400 µL methanol, then mixed with 0.8 mL acetonitrile 
containing around 12 mg PGMD polymer. The mixed solution was added to 12 mL 0.1% 
pluronic while stirring at 930 rpm. The organic phase was removed by evaporation for 24 
hours at room temperature. The NPs were then collected and centrifuged at 5000 rpm for 
5 minutes to remove large NPs. 
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Next, the supernatant was collected and any free DOX or IR820 was filtered out using a 
dialysis membrane at MWCO 1,000 Da. The dialysis process was continued for 24 hours. 
Finally, the particles were freeze-dried and lyophilized for 48 hours. Void PGMD NPs 
were prepared following a similar method except for the addition of DOX and IR820. 
IR820-PGMD NPs were also prepared following the same protocol, except that no DOX 
was added. 
3.1.2. Characterization of PGMD polymer, void PGMD NPs, IR820-PGMD NPs and 
DOX-IR820-PGMD NPs 
3.1.2.1. Characterization of PGMD polymer 
Glass transitional temperature (Tg) of PGMD was measured through differential scanning 
calorimetry (DSC) by using a DSC 2910 (TA instrument, New Castle, DE). Fourier 
transform infra-red (FTIR) spectra were obtained through a Perkin Elmer Spectrum 1000 
spectrometer (Perkin Elmer, Waltham, MA). The molecular weight (MW) of the polymer 
was determined by a calibration curve of standard polystyrene (TSKstandard polystyrene, 
TOSOH, Japan) measured with a gel permeation chromatography (GPC) column (Jordi 
lab, Bellingham, MA) at 0.5 mL/min flow rate in THF. 
3.1.2.2. NPs size, size distribution and zeta potential 
Void PGMD NPs, IR820-PGMD NPs and DOX-IR820-PGMD NPs size were measured 
by dynamic light scattering (DLS) using a Malvern Zetasizer (Malvern Instruments, 
Worcestershire, United Kingdom). Size measurements were taken at 25°C using a 1:30 
(vol/vol) dilution of the NPs suspension in deionized (DI) water. The polydispersity 
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index (PDI) was used as a measure of particle size distribution. Zeta potential (surface 
charge) of the NPs dispersed in DI water was measured by the same Zetasizer. The size 
of void PGMD NPs was confirmed with SEM (SEM, JEOL-JEM). 
3.1.2.3.Drug loading  
The NPs were dissolved in DMSO (1 mL), and the absorption spectrum of the samples 
was evaluated using a Cary spectrophotometer (Varian, Palo Alto, CA). Serial dilutions 
of the sample was done to reach the linear range (1:2, 1:4, 1:8, 1:16, 1:32, 1:64 dilutions). 
The maximum peak intensities were corrected with DMSO blank subtraction and were 
plotted and fitted to a linear model. Then, the concentration of DOX and IR820 in the 
NPs were determined using a standard calibration curve of DOX and IR820 in DMSO 
using the same spectrophotometer. IR820 concentration in IR820-PGMD NPs was 
measured following the same method using a calibration curve of IR820 in DMSO. 
3.1.3. NIR laser-IR820 HT delivery system 
3.1.3.1. System set-up 
In order to deliver rapid HT to the cells, IR820 has to be first taken up by cells and then 
activated by a NIR laser. For this purpose, a laser heating system was designed (55). The 
system includes a laser module (RLDH808-1200-5, Roithner Laserthchnik, Austria), a 
laser holder, a heated stage insert (WPI Heated Stage Insert, World Precision Instruments 
Inc, Sarasota) and a mobile stage with an extension arm. External cover of the system is 
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also designed for safety consideration; power supplies for the laser and the heated stage 
insert are also placed outside the box for the same reason.  
During operation, the whole system is covered within a wooden box to eliminate effects 
of air currents and also to prevent the laser light from exiting. The laser module is fixed 
to a holder, so that its beam is perpendicular to the 96-well plate which is placed on the 
heated stage insert. The heated stage insert is powered by an external source to ensure 
that the plate is at 37°C prior to the laser application.   
The NIR laser source emits light at 808 nm with an output power of 1.2 Watts. The 
calculated power density is 1440 J/cm2. This small spot size guarantees that only one well 
is excited at a time. The exact positioning of a well with the laser beam is achieved by 
moving the stage with an extension arm. The arm is used to move the wells in the plate, 
thereby allowing different wells to be exposed to the laser one at a time without opening 
the box.  
To verify the positioning of the laser relative to the wells, an infrared beam finder card 
(IRC-42R) is used to visualize the NIR laser beam while wearing protective goggles. At 
the same time, the specific well under exposure and its relative position outside the box is 
indicated by a position indicator on another 96-well plate. After moving through A1 to 
H12 of a 96-well plate using the moving stage, the relative position outside the box is 
recorded for future use. Necessary safety measures are taken and personal protective 
equipment used during experiments, especially appropriate engineering and 
administrative controls. 
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3.1.3.2. System calibration 
Temperature calibration studies were carried out with the NIR laser system. The purpose 
is to find the optimal settings for the heated stage insert controller so that a well filled 
with 222 µL of media could be maintained at 37°C. The temperature distribution across 
the entire 96-well plate when using the heated stage insert is monitored. During this 
calibration process, a 96-well plate filled with 222 µL of media is placed on the heated 
stage insert and the settings on the heated stage controller adjusted so that the temperature 
in the wells is at 37°C. Twenty minutes time interval is given for steady state heat 
transfer. Finally, the temperature of each well is recorded with a thermocouple, which is 
inserted into a 96-well plate to measure the medium temperature change to generate a 
temperature distribution profile. The temperature distribution of the 96-well plate is 
shown in Table 1 (55).  
 1 2 3 4 5 6 7 8 9 10 11 12 
A 29.3 33 35.8 36.1 36.8 35.9 36.9 36.9 36.8 35.7 33.2 29.8 
B 30.2 34.4 36.8 36.7 37.1 36.8 36.5 36.9 36.6 36.8 34.8 32.7 
C 32.5 35 37.4 37.1 37.2 37.1 37.2 37.3 37.1 37.2 35.7 33.8 
D 35.2 35.6 37.5 37.4 37 36.0 36.9 37.4 37.2 37.3 35.7 34.1 
E 32.3 35.5 37.6 37.2 37.1 35.1 37.4 37.1 37.3 37.1 35.9 33.9 
F 33.4 35.4 37 37.1 37.1 36.9 37.1 37.1 37.5 37.1 35.8 33.7 
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G 31.1 34.1 36.5 36.8 36.9 36.7 37.5 37.2 37.4 36.7 35.1 31.3 
H 29.1 33.2 35.7 35.9 36.5 36.4 37.1 36.9 36.7 35.8 34.7 29.6 
Table 1. A 96-well plate temperature distribution when placed on the heated stage insert. 
Since there is a hole in the center of the heated stage, which results in a non-
homogeneous temperature distribution in the 96-well plate, we designed our experiments 
accordingly to use the wells which can reach the temperature between 36.5°C – 37.5°C 
(bold).  
3.1.3.3. Heating capacity of free IR820 and IR820 in IR820-PGMD NPs and DOX-
IR820-PGMD NPs 
We prepared 2.5 μM, 5 μM, and 10 μM solutions of IR820 or NPs which have equivalent 
concentration of IR820. Each sample was added to three wells in a 96-well plate sitting 
on the heated stage insert, and excited with the laser system described in section. 3.1.3.1. 
for 180 seconds. Temperature inside the well was measured with a thermocouple for the 
duration of exposure, and the three-well values for a given dye were averaged. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B   M  2.5  5  10    
C             
D   M  2.5  5  10    
E             
F   M  2.5  5  10    
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Table 2. Schematic of IR820 study design for measuring temperature profile in a 96-well 
plate (n=3); M: wells with only media; wells labeled with 2.5, 5, 10, indicates the final 
concentration of IR820 in the well. 
The goal of this study was to find out an optimal concentration at which IR820 is able to 
heat up the cells to approximately 42°C quickly. A volume of 22 µL of free IR820, 
IR820-PGMD NPs, or DOX-IR820-PGMD NPs at IR820 concentrations of 25 µM, 50 
µM, and 100 µM were added to the wells that were originally loaded with 200 µL media 
to achieve final concentrations of 2.5 µM, 5 µM, and 10 µM.  
3.1.4. Incubator-induced HT and temperature profile  
In order to mimic conventional whole body HT, a Hera incubator was used as the energy 
source. The temperature of the incubator was set to 42°C. Ninety-six-well plates, which 
were originally incubated in the 37°C incubator, were transferred to the 42°C incubator. 
To study the temperature profile of incubator HT, we first placed the thermocouple inside 
the incubator and the sensor tip was inserted into a 96-well plate to measure the medium 
(222 µL) temperature change.  
3.1.5. Thermal dose calculation 
The term “thermal isoeffective dose” is used to compare different time-temperature 
combinations which produce the same cell killing effect. This method was used since the 
cell death rate under HT is exponentially related to both time and temperature. The 
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relationship of time and temperature can be expressed mathematically by the following 
isoeffect equation: 
ݐଵ ൌ ݐଶ ∗ ܴ భ்ି మ்           (Equation 1) 
where t1 & t2 are the duration of treatment at temperature T1 & T2, respectively. 
Originally, R is a function of temperature, however, an estimation of R as a constant will 
give an error of less than 2% in the temperature between 37°C to 46°C described by 
Sapareto et al. (110). Hence, R is assumed to be 0.5 above 42°C and 0.25 below 43 °C 
(110). Based on Equation (1), different thermal doses can be converted to the cumulative 
equivalent minutes at 43°C (CEM43). From Equation (1), we did a slight modification and 
set T1 to be 42°C and T2 to vary during heat treatment, so that we obtain Equation (2). 
The integral upper limit t is the end time of the experiment (3 minutes or 60 minutes). 
ܥܧܯସଶ ൌ ׬ ܴସଶି்ሺ௧ሻ݀ݐ௧଴ 	           (Equation 2) 
After obtaining the temperature profile during both incubator and laser/Dye/NP HT, the 
CEM42 model was applied to calculate the thermal doses in each treatment.  
3.1.6. In vitro studies of void PGMD NPs, IR820-PGMD NPs and DOX-IR820-PGMD 
NPs 
To fulfill this part of aim 1, human uterine sarcoma MES-SA cells, and their MDR (P-gp 
overexpressing derivative MES-SA/Dx5 (Dx5)) cells, human ovarian carcinoma cancer 
cells (SKOV-3), McCoy's 5A medium, and fetal bovine serum were purchased from 
American Type Culture Collection (Manassas, Virginia). 24-well tissue culture plates, d-
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poly coverslips, and formalin were purchased from Fisher Scientific. All the cells were 
cultured in McCoy's 5A medium added with 1% penicillin and 10% fetal bovine serum, 
and kept in a 37°C cell incubator with a humidified atmosphere of 5% CO2 and 95% air.  
3.1.6.1.IR820 and DOX release kinetics profile from DOX-IR820-PGMD NPs  
Briefly, 5 mg of DOX-IR820-PGMD NPs were resuspended in 3 mL of 0.01 M PBS 
(pH=7.4 or pH=5.0). Next, the sample was divided equally into three Eppendorf tubes, 
which were shaken at 35 rpm at 37°C in an incubator. The tubes were then removed from 
the incubator every hour up to the first 5 hours, and then after 24 hours. Each time, the 
samples were centrifuged at 14,000 rpm for 30 minutes. Following this, the supernatant 
was collected in 4.5-mL cuvettes, and the DOX and IR820 content were estimated using 
a spectrofluorometer (Jobin Yvon Horiba, Edison, NJ). The NPs were again suspended in 
fresh PBS solution and incubated for later time release measurements. This process was 
repeated at regular time intervals, every 7 days after the first day, for a period of 29 days. 
The release of DOX from DOX-IR820-PGMD NPs after exposure to laser in different pH 
was also studied. Briefly, the NPs were measured and resuspended in 3 mL PBS with 
different pH (pH=7.4 or pH=5.0) to obtain 5 µM IR820. Then, the suspension was 
exposed to an 808-nm NIR laser (RLDH808-1200-5, Roithner Laserthchnik, Austria) for 
3 minutes with power density of 1440 J/cm2. Finally, the suspension was centrifuged and 
processed as previously described. 
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3.1.6.2. IR820 release kinetics profile in IR820-PGMD NPs 
IR820 release kinetics study followed the protocol described in section. 3.1.6.1. IR820 
release measurements in different pH PBS were performed only up to 24 hours because 
the fluorescence intensity of IR820 becomes unstable after 24 hours. Also, IR820 release 
was not measured after laser exposure to NPs since photobleaching occurs after laser 
excitation.  
3.1.6.3. DOX cellular uptake experiments 
Two cell lines (MES-SA and Dx5) were used to study the cellular uptake of 
unencapsulated DOX and IR820 (designated as free DOX + IR820) and compare with the 
uptake of the NP formulation. On the first day, the cells were seeded into 24-well plates 
at a cell density of 100,000 to 200,000 cells per well. On the second day, the cell medium 
was removed, and free DOX + IR820 or DOX-IR820-PGMD NPs in growth medium was 
added to the plates at a normalized DOX concentration of 4 μM (2.3 μg/mL). The plates 
were then placed back in a cell incubator for 24 hours. The control group means no drug 
was added. After 24 hours, the cell medium was removed, and the cells were washed with 
ice cold DPBS four times and then lysed with 1 mL of DMSO. The supernatants were 
centrifuged at 14,000 rpm for 10 minutes and collected to obtain cell lysates. The DOX 
fluorescence intensity of cell lysates was measured by a spectrofluorometer (Jobin Yvon 
Horiba, NJ) at λex = 482 nm, λem = 590 nm to determine DOX concentration. To adjust 
the background fluorescence from cellular components, a DOX calibration curve was 
created by dissolving DOX and IR820 in DMSO and adding the solution to untreated 
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cells. The protein content in the cell lysates can be measured using a micro BCA protein 
assay kit, and the absorption data was acquired at 562 nm with the same 
spectrophotometer. Cellular uptake of DOX for different treatments was calculated by 
normalizing the DOX amount to the protein amount. An average value was obtained from 
three wells in each treatment for each experiment, and an average (± SD) intracellular 
uptake of DOX from three experiments was plotted. 
3.1.6.4. Subcellular localization 
To study the intracellular localization of free IR820, IR820-PGMD NPs and DOX-
IR820-PGMD NPs, cells were seeded with a density of 4 × 104 cells per well inside wells 
of a 24-well tissue culture plate, and incubated overnight to reach confluence. On the 
second day, cell medium was removed and then replaced with 0.5 mL of 5 µM IR820, 
0.05 mg/mL IR820-PGMD NPs (5 μM IR820) and 0.05 mg/mL DOX-IR820-PGMD NPs 
(4 μM DOX plus 5 μM IR820). The plates were kept in a 37°C incubator for 24 hours 
and protected from light exposure. After incubation, cells were washed with PBS three 
times and fixed with 4% (vol/vol) formaldehyde. Then, the specimens were observed by 
fluorescence microscopy (Olympus IX81, Japan) with a 20X objective or 60X water 
merged objective. The fluorescence was imaged at λex (490 nm), λem (580 nm) for 
DOX, λex (775 nm), λem (845 nm) for IR820. A CCD camera was used to capture the 
signals and the images were software-merged with pseudo color (IPLab, Qimaging, 
Canada).  
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For the subcellular localization study of free IR820 and IR820-PGMD NPs. The images 
were recorded at the same exposure time for both of the treatments in SKOV-3. The 
acquired fluorescence images were processed by Matlab (MathWorks, Massachusetts) to 
calculate the image ratio R. First, the intensity of each pixel was background image 
subtracted, and a region of interest was defined as being composed of any pixels with 
above-background intensity values (defined as an intensity of at least 2 out of a 255 scale 
after background subtraction). Background cell images were taken without turning on the 
fluorescence lamp. The ratio R was then determined by normalizing the total pixel 
intensity of this region of interest to its total area. 
Lysotracker Blue (Invitrogen, NY) and SKOV-3 were used to identify the subcellular 
localization of IR820-PGMD NPs with λex (355 nm), λem (420 nm). SKOV-3 cancer 
cells wereused because of their larger size compared to MES-SA and Dx5, which makes 
it easier to identify the localization of Lysotracker Blue. All the subcellular localization 
experiments were carried out as described before, with the addition of 5 µM Lysotracker 
Blue to SKOV-3 at the end of the treatment and incubation with cells for 5 minutes.  
3.1.6.5.Cytotoxicity assessment 
Cell viability was measured with the sulforhodamine B (SRB) assay (Invitrogen, NY), 
which colorimetrically measures cellular protein. In this study, the cytotoxicity of nine 
different treatments (laser only group, free IR820, free DOX plus IR820, IR820-PGMD 
NPs, DOX-IR820-PGMD NPs, IR820 w/ laser, free DOX plus IR820 w/ laser, IR820-
PGMD NPs w/ laser, DOX-IR820-PGMD NPs w/ laser) were investigated. The detailed 
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procedure is the same as we have described in our previous paper (55). Briefly, cells were 
seeded in a 96-well plate on the first day, and after overnight incubation they were 
exposed to different treatments. The cytotoxicity was measured with the SRB assay 24 
hours post treatment. Tested DOX and IR820 concentrations were at 5 μM. We also 
tested the cytotoxicity of void PGMD NPs at higher concentrations (0.1 mg/mL) than 
those used in the experiment (0.05 mg/mL). An average value was obtained from four 
wells in each treatment for each experiment. Then, an average (± SD) “cell growth” from 
three experiments was plotted against increasing DOX and IR820 concentrations. Cell 
growth values were generated by normalizing the data from each treatment to the control 
values, which did not receive any treatments. Cell growth was calculated by the 
following formulas: (Tx−To)/(C−To) * 100 if Tx>To, and (Tx−To)/To * 100 if Tx<To. 
SRB value To is defined as the initial amount of cells; Tx corresponds to the treatment 
values; C is SRB value from the controls, which did not receive any treatments. Cell 
growth was plotted against DOX concentration to show toxicity effects as described by 
Monks et al. (111) and also used previously by our group (55). If Tx>To, the treatment is 
considered as growth inhibition; if Tx<To, there is no net cell growth after the treatment, 
so its effect is considered as cell killing. Statistical significance for sample means of cell 
net growth among treatment groups at the same DOX concentration was identified by 
one-way analysis of variance (ANOVA). 
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3.2. The fulfillment of Specific Aim 2 
All the assays were carried out in the following groups: 
NIR laser-IR820 HT delivery system and incubator HT delivery system, which were 
described in section 3.1.3. and 3.1.4. 
3.2.1. Study of ROS expression    
Intracellular ROS levels was measured using the fluorescent dye 5-(and-6)-chloromethyl-
2′,7′-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA) (Invitrogen, 
NY), which was converted into a nonfluorescent derivative (H2DCF) through cellular 
esterases after uptake by cells. Then, H2DCF can be oxidized to 2′,7′-dichlorofluorescein 
(DCF), which is highly fluorescent in the presence of ROS. Since this assay requires 
fluorescence measurements with excitation around 490 nm, which overlaps with the 
absorption spectrum of DOX, IR820-PGMD NPs were used to measure ROS expression 
in cancer cells. After HT (either 1-hour incubator HT or 3-minutes NIR-laser induced 
HT), cells were washed with PBS and collected by incubating briefly with trypsin. The 
same number of cells were counted and incubated with CM-H2DCFDA at 37 °C with 5% 
CO2 in the dark. After 30 min, cells were briefly washed with PBS, and the intensity of 
DCF was measured by flow cytometer (BD Accuri C6, NJ).   
3.2.2. Study of HIF-1 expression 
To investigate HIF-1 expression in both incubator HT and laser/Dye/NP HT, 
human/mouse Enzyme-Linked ImmunoSorbent Assay (ELISA) was used to detect the 
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expression of HIF-1 using HIF-1α antigen. Basal level HIF-1 expression was identified in 
cells incubated at normal temperature (37°C). HIF-1 expression was measured 
immediately after HT by reading the plate using a fluorescence plate reader (GENios, 
TECAN, CA) with excitation at 540 nm and emission at 600 nm to measure the amount 
of total HIF-1 in the cells. Then the plate was read with excitation at 360 nm and 
emission at 450 nm to measure the amount of total cytochrome c in the cells. In the end, 
the HIF-1 amount was normalized to the amount of cytochrome c and expressed as HIF-1 
activity.  
3.2.3. Study of VEGF expression 
Cancer cell culture medium was collected 6 hours after HT. After centrifuging cell 
culture media for 10 minutes at 16,000 × g, 200 µL of supernatant was added into a 96-
well plate provided in a human quantikine VEGF ELISA kit. VEGF levels were 
quantified following VEGF ELISA kit protocol and SRB assay was used to determine the 
amount of cellular protein in each well. Finally, the measured VEGF amount was 
normalized to SRB value and the calculated results were normalized to controls.    
3.2.4. Cytotoxicity after HT treatment  
Two different heating modalities, including both the incubator and laser/Dye/NP HT 
delivery system, were used for in vitro Cytotoxicity studies. Detailed descriptions of the 
heating systems and the temperature calibration for both heating modalities were 
discussed before in sections 3.1.3. and 3.1.4. Note that when incubator HT was used, 
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cells were incubated with the same concentration of IR820-PGMD NPs as used in 
laser/Dye/NP HT in order to eliminate the effect of NPs by themselves.  
 
3.3. The fulfillment of Specific Aim 3 
3.3.1. Mice models 
Thirty-six Nd4 Swiss Webster mice (25–30 grams, 9 weeks old) were purchased from 
Harlan (Indianapolis, IN), kept under standard housing conditions, and fed ad libitum. All 
protocols followed the regulations of the Institutional Animal Care and Use Committee. 
Mice were randomly assigned to different experimental groups based on different time 
points, namely 15 minutes, 30 minutes, 60 minutes, and 24 hours. On the day of the 
experiment, the animals were anesthetized and injected through the tail vein with a 
solution of NPs in PBS. The concentration of injected NPs was determined based on an 
IR820 dose of 0.24 mg/kg of body weight and an injection volume of 0.2 mL. The choice 
of 0.24 mg/kg was based on the work of Rajagopalan et al., who used a 0.24 mg/kg dose 
of ICG to study its pharmacokinetics in mouse blood (112). Our group subsequently also 
utilized this dose in rat and mice studies of free ICG and free IR820 biodistribution (79). 
The choice of 0.2 mL was based on reported safe intravenous (i.v.) injection volumes for 
mice (113). Therefore, to calculate the amount of free dye/NPs we need to use for animal 
studies: 
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For free dye: 
Injection mass=ሺmouse weight in kgሻ* ൬0.24 mg
kg
൰ 
Free dye solution concentration=
injection mass
0.2 mL
 
For NPs, we need to introduce one more term as IR820 loading to 0.24 mg dye/kg dose:  
Injection mass=ሺmouse weight in kgሻ* ቀ0.24 mg
kg
ቁ /( mg dye
mg NPs
)            
NPs solution concentration=
injection mass
0.2 mL
 
Free dye and NPs were first resuspended in DI water or DPBS to reach the final desired 
concentration and NPs solution was sonicated to make sure they resuspended properly. 
Then, 0.2 mL of the solution was drawn into a 1-mL syringe with a 30g needle, and the 
syringe covered with aluminum foil to protect the drug from light. Before the injection, 
an infrared lamp was used to warm the mouse and facilitate the injection process by 
dilating the tail veins.  
3.3.2. NIR in vivo biodistribution imaging 
To study the biodistribution, we used an imaging system consisting of a Sanyo DL 7140-
201S laser (80 mW, 785 nm) and a Retiga CCD camera (Qimaging, Canada) coupled 
with NIR filter (λex=785 nm, λem=820 nm). The entire setup was covered by BK5 
blackout material during the experiment. On the day of the experiment, the mice were 
first anesthetized by inhalation of isoflurane in a closed chamber, and then injected 
intraperitoneally (i.p.) with pentobarbital. Animals in the 15-minute group received a 100 
mg/kg pentobarbital dose. Animals in the 30-minute and 60-minute time groups, received 
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the same 100 mg/kg dose, but administered as two half-doses. The first 50 mg/kg were 
given before dye injection and imaging, and the additional 50 mg/kg were given 15 
minutes before the terminal time point in order to reach euthanasia levels. This split 
administration protocol was used to ensure that the animals would not die before the 
terminal time point. In the case of the 24-hour group, the animals received a 40 mg/kg 
pentobarbital dose on the first day of imaging, were returned to their cage for 24 hours, 
and received a 100 mg/kg pentobarbital dose before 24-hour imaging.   
 
For all groups, after the administration of pentobarbital, mice were placed on the imaging 
stage and a white light image was acquired with white light illumination to determine the 
position of the mouse. Then, the laser was turned on with white light off to obtain a black 
image as the background prior to dye injection. Laser current was set to 60 mA for 
acquiring optimal fluorescence signal. The exposure time of the images was 10 seconds 
and threshold gain was 3. The camera started recording immediately after the injection. A 
series of images was taken using QCapture Pro software over at least 40 minutes. In the 
24-hour group, one white image and one fluorescent image were taken under the same 
operating conditions 24 hours after the i.v. injection of dye or NPs. After the 24-hour 
imaging protocol was completed, the animal was euthanized by removal of the heart 
while under deep anesthesia, and organs were carefully dissected. The lungs, kidneys, 
liver and intestines were then placed in black-coated Petri dishes and imaged using the 
same imaging setup. Later, the images were processed with Matlab to calculate the image 
fluorescence intensity R as described before in section 3.1.6.4.  
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3.3.3. Pharmacokinetics and biodistribution study  
3.3.3.1.Study Design 
Thirty-six healthy Nd4 Swiss Webster mice were divided randomly to different groups 
with different treatments as shown in Table 3.  
Treatments 15 minutes 30 minutes 60 minutes 24 hours 
Free IR820 Group 1 Group 4 Group 7 Group 10 
IR820-PGMD NPs Group 2 Group 5 Group 8 Group 11 
DOX-IR820-PGMD NPs Group 3 Group 6 Group 9 Group 12 
Table 3. Study design for biodistribution experiments of IR820, IR820-PGMD NPs, and 
DOX-IR820-PGMD NPs. Each group has three mice.  
3.3.3.2.Pharmacokinetics study 
At the terminal time point for all groups (15min, 30min, 60min, and 24h), plasma 
samples were collected in order to study the pharmacokinetic profiles of IR820 and DOX 
after imaging. Plasma samples were obtained by heart puncture followed by 
centrifugation 2x for 3 minutes at 12,000 rpm. Plasma samples were then incubated in 
DMSO (1:50 volume ratio plasma: DMSO) for thirty minutes and centrifuged again at 
6,000 rpm for 15 minutes. The supernatant was used to perform spectrofluorometric 
measurements of dye content using previously created calibration curves of IR820 in 
DMSO at 785 nm excitation, and DOX in DMSO at 482 nm. The in vivo behavior of the 
drug/dye can be estimated based on different models, which are based on the assumption 
that the drug/dye are distributed into one or more so called “compartments”, such as 
organs or body fluids etc. (114). The commonly used model assumes there are input 
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(drug/dye administration), mass transfer in compartments, and output (drug clearance) 
(115). 
The one compartment model is the simplest model, which assumes the drug/dye is 
distributed in the body uniformly and gets eliminated either by metabolism or excretion 
in urine and feces (115). The equation used to describe the one compartment model is 
listed below and assumes the molecule follows a monoexponential decay. 
C(t)=C0× e-kt           (Equation 3) 
C(t) is the concentration as a function of time, C0 is the initial concentration, k is the 
clearance rate, and t is time. Following this equation, the half-life of the molecule, 
defined as the amount of time it takes for 50% of the agent to disappear from the system, 
is calculated by Equation (4): 
t1/2 =
ln (2)
k
         (Equation 4) 
A two-compartment model can also be used to estimate the drug/dye in vivo behavior. 
The assumption of a two-compartment model is that there is central compartment, 
comprised of the plasma and well-vascularized organs such as the liver; and then the 
peripheral compartment, which encompasses the rest of the organism. Molecules injected 
into the system will undergo two distinct processes or phases. In the first phase, 
distribution, mass transfer occurs from the central compartment to the peripheral 
compartment until steady state is reached (114). In the subsequent second phase, 
elimination, the concentration gradient reverses and mass transfer occurs from the 
peripheral to the central compartment. The mass transfer between peripheral and central 
compartment will continue during the elimination process until the molecule is cleared 
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from the body by liver metabolism and kidney excretion (115, 116). Therefore, the 
equation for a two-compartment model is the bi-exponential decay equation in Equation 
(5): 
Cሺtሻ=A×e-at+B×e-bt     (Equation 5) 
where C(t) is the concentration as a function of time; A and B are constants for the 
distribution and elimination process, respectively; a is the rate constant for distribution 
and b is the rate constant for elimination; t is time (115). Therefore, the model has been 
separated into two parts: initial rapid decay phase for distribution and second -slow 
declining phase for elimination. At the starting point (t=0), the sum of A and B is equal to 
the initial drug/dye concentration. 
The distribution process half-life can be calculated as: 
t1/2 =
ln 2
a
         (Equation 6) 
And the elimination process half-life can be calculated as: 
t1/2 =
ln 2
b
         (Equation 7) 
The choice of the compartmental model is usually based on the a priori prediction of 
drug/dye in vivo behavior, the goodness of fit between data and model, and the 
improvement in fit, if any, after using a higher order model.  
3.3.3.3.Pharmacokinetic analysis of plasma data 
In order to estimate the initial injection dose amount, we first calculated the average 
weight of all the mice and obtain an average weight of 25 grams. Then, the initial dose 
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amount can be calculated as approximately 6 µg IR820 based on the 0.24 mg/kg injection 
dosage. The ratio of plasma volume to body weight is 58.5 mL plasma/kg body weight 
given by the literature (117), so we assumed a 25-g mouse has plasma volume 
approximately 1.5 mL. Thus, the initial dose concentration can be calculated to be 
approximately 4 µg dye/mL in plasma. Using five data points (0min, 15min, 30min, 
60min, 24h) and the fit curve toolbox of Sigmaplot (Systat Software, San Jose, CA), we 
can predict the drug/dye physiology decay behavior with monoexponential or 
biexponential model. Since there is no study in the literature investigating the IR820 in 
vivo distribution and elimination behavior, we attempted to generate an in vivo model 
starting from the simplest model. Moreover, IR820 has similar characteristics as ICG, 
and ICG pharmacokinetics had been studied via both one-compartment and two-
compartment model approaches (118). Hence, we started with the simplest 
monoexponential model and then the biexponential model to determine which model to 
be used based on the goodness of the experimental data fit to the models used. For DOX 
pharmacokinetics, there are also studies using both one-compartment and two-
compartment models (119-121), and we also chose the model based on the goodness of 
fit. As a result, the overall half-life (if one-compartment was used), or the distribution 
half-life and elimination half-life (if two-compartment was used) can be calculated based 
on the equations given above. Following the determination of half-lives, we also 
calculated other pharmacokinetic parameters: the area under the pharmacokinetic curve, 
the mean plasma residence time, and the clearance rate.  
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The area under the curve (AUC) is the integral of drug/dye concentration vs. time curve, 
which can be calculated by Simpson’s rule.  
Area under the curve (AUC)= ׬ C(t)dt∞0   (Equation 8) 
The mean residence time in plasma (tp) is the average time spent by the drug/dye in 
plasma, and is given by: 
tp=
AUC
C0
   (Equation 9) 
where C0 is the model original concentration.  
The total body clearance rate (CL) (volume of drug/dye cleared from the body vs. time) is 
given by: 
CL= Dose
AUC
  (Equation 10) 
Based on the preceding calculations, we compared free IR820, IR820-PGMD NPs and 
DOX-IR820-PGMD NPs pharmacokinetic parameters using one-way ANOVA (p<0.05). 
3.3.3.4. Quantitative measurement of organ content 
In addition to plasma measurements, in the 24h group the liver, lungs, kidneys, and 
intestines were also extracted. The quantitative measurements of IR820 content in 
different organs after 24 hours were performed by dye extraction in DMSO following the 
procedures described by Saxena et al. for ICG (122) and used by us previously (79). 
Briefly, the dissected organs (liver, lungs, kidneys, and intestines) were collected and 
homogenized. Then, the homogenized tissues were incubated with 5 mL DMSO for at 
least 4 hours to allow the IR820 and DOX to be dissolved. Then, the supernatant was 
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collected and centrifuged at 6,000 rpm for 15 minutes. Next, the fluorescence intensity of 
the supernatant was measured as described above for measuring plasma in section 
3.3.3.2., and the fluorescence intensity was converted to drug/dye concentration in 
DMSO (µg/mL). Finally, dye mass in μg obtained from this measurement was 
normalized to homogenized organ mass in grams. 
3.4. Statistical significance 
Statistical significance was identified by ANOVA or t-test (SPSS, Chicago, Illinois) for 
the difference among treatment groups and control groups. A p-value < 0.05 was 
considered to be statistically significant. 
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CHAPTER 4: RESULTS 
4.1. Results accomplished for Specific Aim 1 
4.1.1. Characterization of PGMD polymer  
The PGMD polymer has a glass transitional (Tg) temperature of 42.2°C, measured by 
DSC. The Tg (~42°C) of PGMD polymer allowed an increased drug release with 
exposure of the NPs to an external heat stimulus. The MW measured by GPC column is 
around 3000 Da. The Fourier transform infra-red spectra (FTIR) showed an intense C=O 
stretch at 1735 cm-1, indicating the appearance of a typical esteric bond (Figure 1).  
 
Figure 1. FTIR spectrum shows the appearance of a C=O stretch at 1735 cm−1, typical of 
ester bonds. 
4.1.2. Characterization of void PGMD NPs, IR820-PGMD NPs and DOX-IR820-
PGMD NPs.  
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The size, zeta potential, polydispersity (PDI), and drug loading efficiency for void 
PGMD NPs, IR820-PGMD NPs and DOX-IR820-PGMD NPs are shown in Table 4. The 
size and shape of void PGMD NPs are also given in DLS measurement (Figure 2), and 
SEM (Figure 3).  
Formulation Size 
(nm)  
Polydispersity
(PDI)  
Zeta 
potential 
(mV)  
IR820 
loading 
(w/w %)  
DOX 
loading 
(w/w %) 
PGMD void NPs  92± 19.6 0.095±0.015  -34.3±1.6  N/A  N/A  
IR820-PGMD 
NPs  
109±8.2  0.151±0.006  -29.1±7.5  8.4±0.5  N/A  
DOX-IR820-
PGMDNPs  
125±19.7 0.182±0.023  -20.3±2.9  8.1±0.6  4.3±0.3  
 
Table 4. Mean size, PDI, zeta potential, and percent of loading efficiencies for void 
PGMD NPs, IR820-PGMD NPs, and DOX-IR820-PGMD NPs (n = 8). 
The NPs are between 50-200 nm range, which can potentially avoid premature clearance 
by the RES. 
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Figure 2. (A) DLS measurement of void PGMD NPs; (B) DLS measurement of IR820-
PGMD NPs; and (C) DLS measurement of DOX-IR820-PGMD NPs. 
The SEM image was used to confirm the size and shape of void PGMD NPs and it 
showed that void PGMD NPs were nearly spherical and uniformly distributed. 
 
Figure 3. SEM image of void PGMD NPs. 
4.1.3. Heating modalities 
4.1.3.1. Incubator HT delivery system and temperature increase profile 
Temperature calibration studies were carried out to find the temperature profile of the 
fluid inside the wells of 96-well plates as shown in Figure 4. The temperature increased 
in incubator HT is very slow, taking approximately 45 minutes to reach 42°C.  
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Figure 4. Temperature curve during 1 hour incubator HT.  
4.1.3.2. Laser-IR820-PGMD NPs HT delivery system and temperature increase profile  
The temperature profile of IR820-PGMD NPs is shown in Figure 5. We used different 
concentrations of IR820-PGMD NPs in order to find out the optimal concentration which 
could induce a temperature increase to between 41°C~45°C. As shown in Figure 5, 0.05 
mg/mL IR820-PGMD NPs, which has 5 µM IR820, can elevate the temperature to 
approximately 42°C. Since this temperature is very close to Tg of PGMD polymer and it 
is sufficient to induce HT effect to cancer cells, we chose to perform our studies based on 
0.05 mg/mL IR820-PGMD NPs/DOX-IR820-PGMD NPs. 
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Figure 5. Temperature profile during 3 minutes laser exposure of different concentration 
of IR820-PGMD NPs. Experiments were repeated 3 times.  
4.1.4. Thermal dose calculation 
A much slower temperature increased was observed in incubator HT compared to the 
temperature increase in laser/Dye/NP exposure. Thermal doses given in these two 
treatments were calculated based on the CEM43 model developed by Sapareto et al. (110) 
as described before. We made a slight modification to use the model at 42°C (CEM42) 
with a smaller empirical value R=0.25. As shown in Table 5, laser/Dye/NP HT for 3 
minutes with 5 µM IR820-PGMD NPs produced a much lower thermal dose as compared 
to the 42°C incubator HT treatment for 1 hour. 
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Table 5. Calculated CEM42 in different types of HT treatment, based on the temperature 
curves in Figures 4 and 5 and using Equations 1 and 2.  
4.1.5. The in vitro studies of void PGMD NPs, IR820-PGMD NPs and DOX-IR820-
PGMD NPs 
4.1.5.1. In vitro drug release 
The release kinetics profile of DOX from DOX-IR820-PGMD NPs is shown in Figure 6. 
In pH 7.4 PBS, the burst release of DOX was around 49% in the first 5 hours, followed 
by a slow release reaching a total of only ~52% after 29 days. When these NPs are 
exposed to the laser for 3 minutes in pH 7.4 PBS at the beginning of the experiment, 5 
µM IR820 is able to increase temperature to approximately 42°C, inducing a rapid 
release of ~81% DOX in 5 hours and 85% in 29 days. Additionally, an acidic 
environment (pH=5.0) can also induce the release of DOX from the NPs to up to ~72% in 
5 hours and 86% in 29 days. DOX release was further enhanced when the NPs were 
placed in acidic buffer and exposed to laser for 3 minutes. Overall, ~90% DOX was 
released in 5 hours and ~95% in 29 days. We observed a very slow release of DOX after 
the initial burst release from NPs in the absence of an external stimulus. However, either 
acidic buffer or heat can induce the release of DOX, indicating that PGMD NPs are 
thermal sensitive and pH sensitive.   
Treatment type CEM42 (min) 
5 µM IR820-PGMD NPs + 3min laser 3.06 
5 µM IR820-PGMD NPs + 42°C incubator 1h 25.98 
56 
 
 
Figure 6. Cumulative percent release of DOX from DOX-IR820-PGMD NPs under 
different experimental conditions. 
The release of IR820 from DOX-IR820-PGMD NPs is shown in Figure 7. IR820 release 
was also enhanced when NPs were placed in an acidic environment. Approximately 48% 
IR820 was released in 5 hours in acidic PBS (pH=5.0), and up to 52% IR820 was 
released in 24 hours. Since the PGMD NPs are pH sensitive, it was expected that an 
acidic environment would induce higher amount of IR820 release from NPs as compared 
to a neutral environment (pH=7.4).  IR820 measurements were performed only up to 24 
hours because the fluorescence intensity of IR820 becomes unstable after 24 hours.  Also, 
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IR820 release was not measured after laser exposure to NPs since photobleaching occurs 
after laser excitation.  
 
Figure 7. Cumulative percent release of IR820 from DOX-IR820-PGMD NPs under 
different experimental conditions. 
4.1.5.2.DOX cellular uptake experiments 
The cellular uptake results are consistent with the literature in that free DOX is taken up 
by cells mainly through diffusion (123), while the NPs formulation is generally delivered 
into cells by endocytosis (124). An improved DOX cellular uptake profile by NPs was 
observed as compared to their free form in the MDR cell line Dx5 as shown in Figure 8, 
probably due to reduced elimination of drug with NPs delivery since NPs formulation can 
overcome the P-gp effect. However, NPs did not result in greater DOX uptake in drug-
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sensitive cancer cell line MES-SA compared to the free drug form, since these cells do 
not have mechanisms to affect drug retention. 
 
Figure 8. 24-hour intracellular DOX uptake in MES-SA and Dx5 cells; n=3 experiments, 
3 wells per treatment. * P<0.05 (by t-test) between NP formulation and NP free form for 
each cell line, indicating significant differences due to loading of DOX into PGMD NPs.  
4.1.5.3.Subcellular localization 
Subcellular localization of 5 µM free IR820 and 0.05 mg/mL IR820-PGMD NPs 
(equivalent to 5 µM IR820) is shown in Figure 9. The subcellular localization of both 
treatments is similar. Free IR820 possibly binds to cytoplasmic proteins such as ligandin 
(125), leading to widespread cytoplasmic localization. In the case of the NP formulation, 
IR820 released from the NPs will behave the same as free IR820, whereas IR820 still 
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within the NPs will be located in endosomes/lysosomes. Images from three different 
experiments of free dye and NPs treatments were chosen for statistical studies for 
fluorescence intensity (n=3) and the R values from the fluorescence microscope images 
show that the NP formulation produces a higher intracellular fluorescence intensity 
(R=3.75±0.54) than does the free dye (R=2.89±0.23) after 24 hours of incubation, 
although the difference is not statistically significant, possibly due to the small sample 
size (n=3 for each group).   
                        
Figure 9. Subcellular localization of free IR820 and IR820-PGMD NPs in SKOV-3 
cells. All images were taken with 60X water-merged objective after 24 hours 
incubation of NPs with cells and merged with pseudo color by software. A. IR820 
fluorescence of free IR820; B. IR820 fluorescence of IR820-PGMD NPs. Scale bar 
represents 20 µm. 
IR820-PGMD NP subcellular localization images are shown in Figure 10. In Figure 10A, 
Lysotracker Blue was used to stain SKOV-3 lysosomes, while Figure 10B shows the 
fluorescence of IR820. Figure 10C, which is the merged image, shows that PGMD NPs 
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are mainly localized in the lysosomes as indicated by the overlap with the Lysotracker 
Blue. This result indicated that most PGMD NPs were probably taken up into cells by 
endocytosis. However, further studies are needed to investigate the specific endocytic 
pathways used by the cells.  
  
  
Figure 10. Subcellular localization of IR820-PGMD NPs in SKOV-3. All the images were 
taken after 24 hours incubation of NPs with cells and merged with pseudo color by 
software (IPLab, Qimaging). A. Lysotracker Blue fluorescence; B. IR820 fluorescence of 
IR820-PGMD NPs; C. merged picture of A and B; D. phase contrast image. Scale bar 
represents 20 µm. 
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As seen in Figure 11A, we observed that some DOX molecules were located in the 
nucleus. Since the free drug accumulates in the nucleus, we would expect the same fate 
for DOX leaked out from NPs (74). On the other hand, DOX molecules that remained in 
the NPs stayed in the cytosol because size limitations prevent the NPs from crossing the 
nuclear pore complex. In Figure 11B, we can see that IR820 stayed in the cytosol for both 
the free form and the molecules that were in NP form. Free form localization is due to the 
possible binding of free IR820 to cytoplasmic proteins such as ligandin (126). In the 
merged picture shown in Figure 11C, the yellow bright dots in the cytosol indicate that 
the NPs are still in the process of releasing DOX and IR820.  
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Figure 11. Subcellular localization of DOX-IR820-PGMD NPs in SKOV-3 cells after 24h 
incubation. A. DOX fluorescence of DOX-IR820-PGMD NPs; B. IR820 fluorescence of 
DOX-IR820-PGMD NPs; C. merged picture of A and B; D. phase contrast image. The 
concentrations of IR820 and DOX were kept at 5 μM and 4 μM, respectively. Scale bar 
represents 20 µm. 
4.1.5.4. In vitro cytotoxicity 
4.1.5.4.1. Void PGMD NPs cytotoxicity profile 
Void PGMD NPs cytotoxicity profile is shown in Figure 12. We tested the NP 
concentration up to 0.1 mg/mL in both MES-SA and Dx5 cells and no toxicity was 
observed in either cell line. The desired NPs concentration (0.05 mg/mL) is based on the 
DOX and IR820 loading result, which is in the safe range of using PGMD NPs.    
 
Figure 12. 24-hour cytotoxicity profile of void PGMD NPs in MES-SA and Dx5.  
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4.1.5.4.2. Cytotoxicity of IR820-PGMD NPs  
Figure 13 shows the cytotoxicity of IR820-PGMD NPs in MES-SA and Dx5 in different 
concentrations. It is shown that IR820-PGMD NPs does not cause any toxicity effect in 
SKOV-3 and Dx5 cells at 0.05 mg/mL (5 µM IR820), whereas it results in approximately 
15% cell growth inhibition in MES-SA. This is probably because the fact that MES-SA 
cells are more sensitive to environmental stressors than SKOV-3 and Dx5. The same 
phenomena was observed when 5 µM free IR820 was incubated with MES-SA cells in 
our previous study (79).  
 
Figure 13. Cytotoxicity of IR820-PGMD NPs.  
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4.1.5.4.3. Cytotoxicity of IR820-PGMD NPs, DOX-IR820-PGMD NPs with exposure 
to laser as compared to free IR820 and free DOX + IR820 
MES-SA and Dx5 cell proliferation following IR820-PGMD NPs, free IR820, DOX-
IR820-PGMD NPs, and free DOX + IR820 incubation w/ or w/o laser exposure is shown 
in Figure 14. A solution of 0.05 mg/mL IR820-PGMD NPs or DOX-IR820-PGMD NPs 
(containing approximately 5 μM IR820) can increase the temperature from a baseline of 
37°C to 42°C following exposure to an 808 nm NIR laser (power density is 1440 J/cm2) 
for 3 minutes, as shown above. Based on this finding, we used a concentration of 0.05 
mg/mL IR820-PGMD NPs/DOX-IR820-PGMD NPs in our study and compared them to 
free IR820/ free DOX + IR820 treatment. Both NP formulations and the free agent 
treatments produced significant cancer cell killing after laser exposure compared to the 
no-laser group due to the HT effect. It is important to note that laser treatment by itself 
does not have an effect on cell growth. 
Our results showed that, although IR820-PGMD NPs seems to have higher cytotoxicity 
than free IR820 after laser exposure in MES-SA, the difference did not reach statistical 
significance. The same phenomena were observed in DOX-IR820-PGMD NPs compared 
to free DOX + free IR820 in MES-SA cells without laser exposure, and the difference in 
cancer cell killing is not statistically significant either. On the other hand, IR820-PGMD 
NPs and DOX-IR820-PGMD NPs showed much higher cytotoxicity than free IR820 or 
DOX-IR820 treatment in Dx5, and the difference is statistically significant (p<0.05). 
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Additionally, the combination of HT and chemotherapy caused enhanced cancer cell 
killing in both cell lines compared to either chemotherapy or HT alone (p<0.05). Based 
on our results, the treatment of the resistant Dx5 cells with NPs containing 4 μM DOX 
and 3 minutes of laser exposure can improve the cytotoxicity and the cell killing effect to 
reach levels comparable to those observed in DOX-sensitive MES-SA cells. 
 
Figure 14. 24-hour cytotoxicity profile of NPs, free IR820 or free IR820 +free DOX  w/ 
or w/o 3 minutes laser exposure in MES-SA and Dx5 cells; n=3, 4 wells/treatment. * 
P<0.05 (by ANOVA) indicates significant differences in cytotoxicity between free agent 
treatment and NPs groups in Dx5 due to the bypassing of P-gp; and ** P<0.05 (by 
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ANOVA) indicates significant differences in cytotoxicity between laser-treated and no-
laser-treated groups due to HT enhancement of cancer cell killing.  
4.2. Result accomplished for Specific Aim 2 
4.2.1. Cellular response after laser/Dye/NP HT and incubator HT  
4.2.1.1. ROS production after HT treatment 
ROS production after two different types of HT is shown in Figure 15. Incubator HT at 
42°C for 1h induced production of ROS in both MES-SA and Dx5 cells, whereas ROS 
production after 3 minutes of 5 μM laser/Dye/NP HT was not different from the control 
cells that were incubated in a 37°C incubator. 
 
Figure 15. Laser/Dye/NP and incubator HT-induced ROS production were measured in 
MES-SA and Dx5 cells. Fluorescent dye CM-H2DCFDA was used to measure the 
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fluorescence intensity and they were normalized to values obtained from the control 
group (37°C). *P < 0.05 indicates significant ROS production was observed in incubator 
induced-HT as compared to control. Laser/Dye/NP induced-HT did not result in 
enhanced ROS production as compared to control (mean ± SD, n = 3). 
4.2.1.2. HIF-1 expression 
As expected, incubator HT induced significantly elevated HIF-1 expression as compared 
to control (p<0.05), while laser/Dye/NP HT did not result in significant changes in HIF-1 
expression. These results suggest that rapid laser/Dye/NP HT, with a much lower thermal 
dose, did not up-regulate HIF-1 expression.  
 
Figure 16. Laser/Dye/NP and incubator HT-induced HIF-1 expression were measured in 
MES-SA and Dx5 cells. HIF-1 activity was assayed using HIF-1 ELISA. All the values 
measured were normalized to the mean value of the treatment at 37°C. *P < 0.05 
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indicates significant HIF-1 expression was observed in incubator induced-HT as 
compared to control. Laser/Dye/NP induced-HT did not result in promoted HIF-1 
expression as compared to control (mean ± SD, n = 3). 
4.2.1.3. VEGF expression 
VEGF expression is shown in Figure 17. It is not surprising to observe that VEGF 
secretion was enhanced after incubator HT, since HIF-1 expression was elevated after 
incubator HT and VEGF is one of the downstream target genes of HIF-1. Accordingly, 
we did not observed significant changes in VEGF expression after laser/Dye/NP HT, 
given that laser/Dye/NP HT did not have any effect on HIF-1 expression.  
 
Figure 17. Laser/Dye/NP and incubator HT-induced VEGF expression were measured in 
MES-SA and Dx5 cells. VEGF secretion was measured using VEGF ELISA. The obtained 
VEGF expression amount was normalized to SRB value as an indicator of cellular 
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protein amount. All the values measured were then normalized to the controls. *P < 0.05 
indicates significant VEGF expression was observed in incubator HT as compared to 
control. Laser/Dye/NP HT did not result in enhanced VEGF expression (mean ± SD, n = 
3). 
4.2.2. Cytotoxicity study 
The laser/Dye/NP HT system described above was used for the cytotoxicity study. 
Significant cancer cell killing was achieved after exposure of IR820-PGMD NPs to this 
laser system. As shown in Figure 18, both incubator HT and laser/Dye/NP induced HT 
significantly killed cancer cells due to the HT effect (p<0.05). Laser/Dye/NP HT 
significantly kills cancer cells better compared to incubator HT (p<0.05) probably due to 
the thermotolerance and cell protective mechanisms not being initiated in the latter group 
(106).  
70 
 
 
Figure 18. 24 hours cytotoxicity profile of IR820-PGMD NPs with laser and incubator 
exposure in MES-SA and Dx5 cells; n=3, 4 wells/treatment. * P<0.05 (by ANOVA) 
between laser/Dye/NP HT and incubator/NP HT, indicating laser/Dye/NP HT results in 
significantly improved cytotoxicity compared to incubator HT. ** P<0.05 (by ANOVA) 
between HT groups and without HT group in both cell lines, indicating significantly 
higher cancer cell killing was achieved due to HT. 
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4.3. Results accomplished for Specific Aim 3 
4.3.1. Biodistribution and pharmacokinetic studies of IR820-PGMD NPs and DOX-
IR820-PGMD NPs  
4.3.1.1. In vivo optical imaging  
In vivo imaging was performed for all the time points mentioned in the Methodology 
section. The images taken at 15min and 24h are shown in Figures 19. These images show 
that the biodistribution of IR820-PGMD NPs and DOX-IR820-PGMD NPs are initially 
very similar to free IR820, as both appear to be processed rapidly though hepatobiliary 
excretion accumulating in the liver within the first 15 minutes. After 24 hours, it seems 
that both free dye and NPs mainly locate in the liver and the organ studies showed that 
considerable IR820 content were also found in the kidney and the lungs, indicating 
uptake by RES. Image ratio R was calculate and given in Table 6, showing that NPs 
resulted in significantly higher IR820 fluorescence intensity than free IR820 24h after 
injection (p<0.05). Note that the image ratio R is only a measurement of normalized 
image intensity per pixel and cannot be used to quantitatively determine in vivo IR820 
concentration.  
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Figure 19. In vivo imaging of free IR820, IR820-PGMD NPs, and DOX-IR820-PGMD 
NPs. (A)-(C) 15min in vivo imaging. (D)-(F) 24h in vivo imaging.  
Treatments R15min R24h 
Free IR820 1.97±0.47 1.42±0.19 
IR820-PGMD NPs 2.20±0.50 *2.37±0.62 
DOX-IR820-PGMD NPs 1.88±0.54 *2.12±0.57 
Table 6. Image ratio R was calculated from fluorescence images of free IR820 and 
IR820-PGMD NPs treatments (n=3). * P<0.05 indicates significant higher fluorescence 
intensity was observed in NPs as compared to free IR820 24 hours after injection.  
4.3.1.2. Pharmacokinetics studies 
The pharmacokinetics study of IR820 concentration in plasma at different time points 
after injection is shown in Table 7. The quantitative dye content analysis showed that 
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IR820 was present in plasma in significantly higher amounts when carried in NPs 
compared to free IR820 24 hours after injection (p<0.05).  
 IR820 IR820-PGMD NPs DOX-IR820-PGMD NPs 
15 minutes 1.94±1.17 3.63±0.20 2.72±0.17 
30 minutes  0.97±0.15 0.73±0.25 1.00±0.21 
60 minutes 0.34±0.03 0.29±0.02 0.50±0.13 
24 hours  0.10±0.01 *0.18±0.05 *0.26±0.06 
Table 7. Plasma concentrations (µg/mL) of IR820, IR820-PGMD NPs and DOX-IR820-
PGMD NPs at different time points after injection. Values represent average±SD (n=3). 
* P<0.05, indicates significant difference between both nanoformulations and free IR820 
24h after injection.  
Based on these results, it seems that NPs have advantages over free dye after initial 
distribution, which confirms our hypothesis that PGMD NPs can enhance the dye plasma 
residence time. The plasma concentration of DOX-IR820-PGMD NPs is also 
significantly higher than free IR820-PGMD NPs after 60min and 24h injection probably 
due to their differences in charge.  
We also measured the DOX plasma concentration at different time points, the results are 
shown in Table 8.   
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Time/Treatments DOX-IR820-PGMD NPs 
15 minutes 1.69±0.48 
30 minutes 1.37±0.16 
60 minutes 1.06±0.13 
24 hours 0.30±0.09 
 
Table 8. Plasma concentrations (µg/mL) of DOX in DOX-IR820-PGMD NPs at different 
time points after injection. Values represent average±SD (n=3).  
4.3.1.3.IR820 Pharmacokinetic modeling 
As discussed in the Methodology section 3.3.3.3., we assumed the initial plasma IR820 
concentration is 4 µg/mL. The IR820 plasma concentration of IR820, IR820-PGMD NPs 
and DOX-IR820-PGMD NPs after injection is shown in Figure 20 on a semi-log scale.  
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Figure 20. IR820 plasma concentration at different time points after i.v. injection of free 
IR820 or IR820 from NPs. The data are expressed in a semi-log scale.  
We used both monoexponential and biexponential models to calculate the IR820 plasma 
half-life, AUC, mean plasma residence time, etc.  The results are shown in Table 9 and 
Table 10. 
a. One-compartment modeling  
Table 9 shows the physiology parameters of IR820, IR820-PGMD NPs and DOX-IR820-
PGMD NPs calculated based on a one-compartment model. 
 IR820 IR820-PGMD NPs DOX-IR820-PGMD 
NPs 
Model equation C(t)=3.984×e-2.805t Cሺtሻ=4.344×e-2.132t C(t)=4.099×e-2.216t 
R2 0.9971 0.8627 0.9674 
 
Table 9. Goodness of fit by using one-compartment model. 
From the table above, we can see that the monoexponential model gives a good fit for our 
data. The coefficient of determination, denoted R2, is 0.99, 0.86, and 0.97 for IR820, 
I820-PGMD NPs, and DOX-IR820-PGMD NPs, respectively. The R2 is not optimal for 
IR820-PGMD NPs probably because of the small sample size or experimental error (n=3 
for each data point). As more data points are acquired, the better experimental data fit is 
estimated.   
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b. Two-compartment modeling 
Table 10 shows the resulting parameters from a two-compartment modeling approach to 
obtain IR820, IR820-PGMD NPs, and DOX-IR820-PGMD NPs data. 
 IR820 IR820-PGMD NPs DOX-IR820-
PGMD NPs 
Model equation Cሺtሻ=3.831×e-3.108t 
+0.1702×e-0.02275t
Cሺtሻ=2.217×e-2.132t 
+2.127×e-2.132t
Cሺtሻ=2.066×e-2.216t
+2.033×e-2.216t
R2 0.9999 0.8507 0.9524 
Table 10.  Goodness of fit by using two-compartment model. 
We used both monoexponential and biexponential models to estimate free dye and NPs’ 
physiology parameters. It is shown that R2 was not improved significantly by changing 
one-compartment model to two-compartment model for estimation of free IR820 
pharmacokinetics, since R2 is already 0.99 with monoexponential model. On the other 
hand, R2 for both NP formulations decreased to 0.85 and 0.95 as compared to the one-
compartment model, respectively. Therefore, it seems the biexponential model did not 
result in improvements for assessment of model accuracy, although the elimination of 
IR820 seems to follow a biexponential pattern. This is probably because the goodness of 
fit is not very good for IR820 loaded NPs plasma data due to the reason that NPs may 
have a different distribution pattern, if we take into account of the IR820 release kinetics 
from the NPs. Therefore, we decided to start from the simplest model and use the one-
compartment model to calculate all the pharmacokinetics parameters.    
Using monoexponential model, we can calculate all the physiology parameters as shown 
in Table 11.   
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 Free IR820 IR820-
PGMD NPs 
DOX-IR820-
PGMD NPs 
Elimination half-life (hours) 0.25±0.005 0.33±0.022*  0.31±0.006*  
AUC [µg*h/mL] 1.42±0.028 2.04±0.137*  1.85±0.038*  
Mean plasma residence time, tp  (h) 0.36±0.007 0.51±0.034*  0.46±0.009*  
Total body clearance rate (mL/h) 4.22±0.084 2.94±0.198*  3.24±0.066*  
Table 11. Pharmacokinetic parameters calculated based on one-compartment analysis of 
dye data in mice. Data represent mean ± S.D. * P<0.05, indicates significance difference 
between NPs and free IR820. 
As expected, NPs resulted in longer elimination half-lives, larger AUC, longer plasma 
residence times, and slower body clearance rates than free IR820. The monoexponential 
calculated plasma half-lives for free IR820, IR820-PGMD NPs, and DOX-IR820-PGMD 
NPs were approximately 14.5 minutes, 19.5 minutes, and 18.7 minutes, respectively. The 
bioavailability of IR820 is increased by using NPs, as the elimination half-life of IR820-
PGMD NPs and DOX-IR820-PGMD NPs is 1.4 times and 1.3 times the free IR820 
elimination half-life, respectively. All the calculated physiology parameters indicated 
prolonged blood circulation with nanoformulation and the cumulative exposure to body 
organs is also enhanced, similar results were also reported in other studies (127, 128).  
4.3.1.4.DOX pharmacokinetics modeling 
Based on the loading efficiency of DOX in DOX-IR820-PGMD NPs, and an IR820 dose 
of 0.24 mg/kg, the initial concentration of injected DOX in plasma was approximately 2 
µg/mL. Therefore, the DOX plasma concentration of DOX-IR820-PGMD NPs at 
different time points after injection was plotted in Figure 21. 
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Figure 21. DOX plasma concentration at different time points after i.v. injection in DOX-
IR820-PGMD NP treatment. 
We also used both one-compartment model and two-compartment model to assess the 
goodness of model fit to the experimental data as shown in Table 12.  
 
Table 12.  Goodness of fit by using one or two-compartment model. 
As shown in Table 12, it seems that the biexponential model may provide a better 
understanding of our data as R2 was improved from 0.94 to 0.99 when a biexponential 
model was used instead of a monoexponential model. Moreover, the introduction of 
 One-compartment model Two-compartment model 
Model equation C(t)=1.985×e-0.66t Cሺtሻ=1.356×e-1.167t+0.6535×e-0.0327t 
 
R2 0.9453 0.9989 
79 
 
distribution phase also gives us insight into the DOX-IR820-PGMD NPs distribution and 
elimination behavior. Hence, we decided to calculate all the physiology parameters 
following the use of a two-compartment model. All the values are shown in Table 13.  
Distribution half-life (hours) 0.59±0.0008  
Elimination half-life (hours) 21.2±0.028  
 AUC [µg*h/mL] 12.03±0.016  
Mean plasma residence time, tp  (h) 3.01±0.004  
Total body clearance rate (mL/h) 0.5±0.0007  
 
Table 13. Pharmacokinetic parameters from two-compartment analysis of dye data in 
mice.  Data represent mean ± S.D.  
From Table 13, the calculated plasma half-lives were approximately 36 min (distribution 
half-life) and 22 hours (elimination half-life). It seems DOX plasma half-life is also 
enhanced when they are encapsulated in NPs. This is a significant improvement over 
literature reports for free DOX which described a distribution half-life of ~2 minutes and 
elimination half-life of ~10.3 hours in mice (129).  
4.3.1.5. Organ dye content  
Table 14 shows the average dye content in µg dye/g tissue for liver, lungs, intestines and 
kidneys 24 hours after an i.v. injection of IR820, IR820-PGMD NPs, and DOX-IR820-
PGMD NPs. Our organ studies showed that IR820, both when in free form and 
encapsulated into NPs, are processed primarily by hepatobiliary excretion and starts to 
accumulate in the liver within 5-10 minutes after injection. However, organs such as the 
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kidney and the lungs also have considerable contents of IR820 after 24 hours, indicating 
uptake by the RES. DOX-IR820-PGMD NPs demonstrate significantly lower dye content 
in the kidneys compared to the free dye (p=0.04), and 2.6 times smaller dye content in the 
liver, although the latter did not reach a statistically significant difference from free 
IR820 (p=0.08).  As for the IR820-PGMD NPs, dye content was lower in kidneys and 
lungs, but the difference also did not reach statistical significance. The lack of statistical 
significance is probably due to the small number of subjects used in the study as well as 
individual variability. DOX organ content after 24 hours injection was not detectable in 
any tissue samples; that is, the DOX fluorescence intensity was not greater than the 
background autofluorescence, probably due to the sub-therapeutic DOX dose used in this 
study. Based on the results, we can say that DOX-IR820-PGMD NPs demonstrate 
decreased renal clearance compared to free dye.  
 
Table 14. Quantitative organ content 24 hours after i.v. injection of IR820, IR820-PGMD 
NPs, and DOX-IR820-PGMD NPs. Values represent average±SD. *P<0.05 indicates 
significant difference between DOX-IR820-PGMD NPs and free IR820 values for 
kidneys. 
 
24h organ and plasma IR820 dye 
content (n=3)  
Liver 
(µg/g) 
Lungs 
(µg/g) 
Intestines 
(µg/g) 
Kidneys 
(µg/g) 
IR820 0.21±0.11 0.28±0.03 0.05±0.006 0.41±0.11 
IR820-PGMD NPs 0.21±0.09 0.23±0.07 0.07±0.02 0.25±0.09 
DOX-IR820-PGMD NPs  0.08±0.01 0.26±0.08 0.05±0.02  *0.21±0.04 
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CHAPTER 5: DISCUSSION AND CONCLUSIONS 
5.1.Characterization of PGMD polymer 
The MW of PGMD polymer is around 3000 Da, which is consistent with the literature 
stating that polycondensation of monomers would preferentially yield low MW polymers 
(130). When high MW polymers are desired, ring opening polymerization is preferred 
(131). Jesus et al. synthesized a polyester dendritic scaffold based on the monomer unit 
(2,2-bis(hydroxymethyl)propanoic acid), and measured a polymer MW around 4000 Da 
(132). The PGMD NPs we obtained are in the 100-150 nm range, which can potentially 
avoid premature clearance by the reticuloendothelial system (133). The loading of IR820 
is sufficient to induce HT without causing cytotoxicity by NPs themselves. Loading of 
IR820 and DOX into the PGMD NPs increased the PDI of the NPs as compared to void 
NPs. Cheng et al. reported that increased PDI was observed with increasing loading 
amount of docetaxel into PLGA–PEG (polyethylene glycol) NPs (134). The observed 
increase in DOX-IR820-PGMD NPs zeta potential after addition of DOX and IR820 as 
compared to void PGMD NPs may be caused by a zeta potential change towards neutral 
due to incorporated DOX amino groups.  
5.2.In vitro release of DOX and IR820 
In our previous work, we developed a multifunctional system by loading ICG (as 
imaging/HT agent) and DOX (chemotherapy agent) into PLGA NPs. Our studies showed 
that ICG-DOX-PLGA NPs are able to bypass the P-gp pump in MES-SA/Dx5 cells and 
are able to induce a synergistic effect by enhancing the cancer cell killing compared to 
82 
 
chemotherapy alone or HT alone (106). However, DOX release from ICG-DOX-PLGA 
loaded NPs is very slow with approximately 50% still retained in the NPs after 30-day 
incubation in pH=7.4 phosphate buffered saline. The DOX release profile was not 
improved even after exposing the NPs to NIR laser, which elevated the temperature to 
~43°C due to the presence of the ICG. It seems that PLGA NPs are not sensitive to 
external heat (~43°C) probably due to the high Tg (45°C-50°C) and high MW (40,000-
75,000 Da) of the PLGA used, which could have a large effect on the release rate (135). 
Furthermore, the unmodified PLGA is hydrophobic, which in many cases limits its 
applications to encapsulation of hydrophobic drugs.   
The release of DOX from PGMD NPs was increased after exposure to laser. This is 
perhaps because of the phase change of PGMD polymer (Tg=42.2°C) at high 
temperatures, which increases the release of DOX from the polymer matrix. There are 
several synthetic polymers sensitive to temperature change, such as acrylamide-based 
hydrogels, especially poly[N-isopropylacrylamide] (PNIPA) hydrogel, and elastin-like 
polypeptides (136-138). Zhang et al. reported that a synthetic PNIPA hydrogel releases 
20-30% more of its 5-fluorouracil load at 37°C compared to 10°C (139). In addition, 
acidic environment can also induce higher DOX and IR820 release, probably due to the 
accelerated hydrolysis of PGMD polymer (140).  
It is well documented that tumor interstitium has lower pH than blood and healthy tissue 
(141, 142). Therefore, a rapid release of DOX from PGMD NPs in an acidic environment 
could be beneficial in cancer therapy. Moreover, the heating of IR820 by an external NIR 
laser can further induce release of DOX at tumor site. Generally, DOX release from the 
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NPs was faster in the burst release phase as compared to our previous study of DOX 
release from PLGA NPs (143), which is probably due to the fact that PGMD has a much 
lower molecular weight compared to the PLGA used in that study (3 kDa v.s.75 kDa). 
Zolnik reported that polymer MW is a key factor in determining release rate, and slow 
release was observed in high MW polymers (70 kDa) (135). On the other hand, PGMD is 
more hydrophilic than PLGA due to the addition of malic acid in the polycondensation 
process. Thus, when using these two polymers to synthesize NPs, the PLGA NPs are 
estimated to have a stronger hydrophobic-hydrophobic interaction with DOX than PGMD 
NPs do, which could be another reason that a higher amount of DOX was released from 
PGMD NPs compared to PLGA NPs for the same time period.  
After exposure of the NPs to both acidic environment and laser irradiation, we observed a 
further enhanced release of DOX from PGMD NPs. This is probably because of the 
combination of physical and chemical effects as described above. The temperature of 
NPs after laser exposure can increase the PGMD polymer Tg, which may cause the NPs’ 
physical properties to change resulting in the transition of amorphous materials from non-
crystalline solid, relatively hard state to a molten state. The physicial property changes 
could possibly soften the polymer and enlarge the NPs pore size, which may result in a 
nonreversible increase in polymer hydrolysis since it becomes easier for water molecules 
to penetrate the polymer and swell the particles. The enhanced hydrolysis could 
accelerate the degradation of the polymer and induce higher diffusion of DOX from the 
polymer matrix. 
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5.3.Subcellular localization of DOX and IR820 in DOX-IR820-PGMD-NPs and 
Uptake of NPs 
In the subcellular localization study, DOX fluorescence was detected in both the cytosol 
and the nucleus. We have demonstrated that the fate of PGMD NPs is mainly localizing 
in lysosomes. Some of the NPs are able to escape endolysosomal degradation and release 
their payload in the cytosol. The escape process primarily takes place through selective 
reversal of the NPs’ surface charge (from anionic to cationic) in the acidic endo-
lysosomal compartment, causing the NPs to interact with the endo-lysosomal 
compartment membrane and to escape into the cytosol (144). The subcellular localization 
of IR820 in both IR820-PGMD NPs and DOX-IR820-PGMD NPs treatments is very 
similar since IR820, once released from NPs, possibly binds to cytoplasmic protein such 
as ligandin (125).  
The cellular uptake of NPs could be affected by their charge and shape. Zhang’s group 
reported that spherical NPs had a higher cell entry rate into Chinese hamster ovary cells 
than cylindrical NPs (145), whereas Chithrani et al. reported a lower uptake of rod-
shaped gold NPs into HeLa cells compared to spherical shaped NPs (146). On the other 
hand, Liang et al. and Chung et al. reported that slight positively charged NPs gave the 
greatest uptake efficiency as compared to neutral and negatively charged NPs (147, 148). 
It seems spherical shape and slightly positive NPs are more efficiently taken up by cells 
compared to other shapes and negatively charged NPs. These studies show that the 
selection of the NPs are very important and can influence the NPs uptake by cells. Hence, 
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the optimization of such parameters should be considered in the design of NPs in order to 
improve the NPs delivery for various biomedical applications. 
5.4.Cytotoxicity 
The NPs result in significantly higher cell killing than does free IR820 or free IR820 plus 
DOX in Dx5, but not in MES-SA cells. This is because MES-SA is a sensitive cell line 
which does not overexpress P-gp, so the NPs do not provide an advantage in increasing 
cellular uptake over the drug’s free form. All these results are in accord with the cellular 
uptake study, in which we observed comparable DOX cellular uptake of DOX-IR820 and 
DOX-IR820-PGMD NPs in MES-SA cells, whereas when the DOX was encapsulated in 
the NPs, the result was a much higher uptake of DOX in Dx5 cells compared to the 
uptake of DOX without the NPs. Our previous study of DOX-PLGA NPs had shown that 
NPs can overcome the P-gp pump efflux effect and increase the uptake and cytotoxicity 
in MDR cell lines, because the NPs formulation can protect the drug from being 
recognized by the P-gp pump (35). Our current study result also showed that the drug 
loaded NPs kill more Dx5 cells after exposure to laser as compared to free IR820 or free 
IR820 plus DOX (p<0.05). Improved cancer cell killing can be achieved with a 
combination of HT and chemotherapy. Our previous study demonstrated that mild cell 
apoptosis can be induced by mild HT (106). Furthermore, the therapeutic effect of DOX 
can be potentially augmented because mild HT can enhance cell membrane permeability 
and fluidity, and in turn result in greater accumulation of the drug inside cancer cells, 
especially for MDR cancer cells. 
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In this study, we used two different heating modalities: 3 minutes laser/Dye/NP HT and 1 
hour incubator HT, and the thermal doses for each were calculated to be approximately 3 
minutes and 26 minutes, respectively, based on the CEM42 model. The model was 
modified from the commonly used CEM43 model. IR820 was still able to cause a 
temperature increase after laser exposure, even after being encapsulated into NPs, which 
is comparable to the temperature increase achieved with free IR820. Thus, it was shown 
in cytotoxicity studies that laser/Dye/NP induced HT caused significantly higher cell 
killing than incubator HT, although a much lower thermal dose was given to the cells 
(approximately 9 times less than with incubator HT). In the commonly used thermal dose 
CEM43 model, in which thermal dose is normalized to cumulative equivalent minutes at 
43°C (110), temperature and duration of heating can be used to define thermal damage. 
Our previous paper and other groups’ reports demonstrated that the rate of photothermal 
treatment might also be affecting HT outcome, since the cells are not able to initiate the 
protective mechanism by inducing heat shock protein expression which would help to 
reduce DNA damage (55, 149). Although the laser/Dye/NP HT produced approximately 
9 times less thermal dose than incubator HT, it still resulted in significantly higher 
cytotoxicity than incubator HT, thus confirming the importance of heating rate. Note that 
the final temperature reached in both modes of HT was identical.  
5.5. Study of ROS, HIF-1, and VEGF 
Following the cytotoxicity study, we were interested in investigating the effect of rate and 
amount of thermal dose to cells by exploring ROS generation, HIF-1 and VEGF 
expression. HIF-1, as an important therapeutic target gene for cancer therapy, was studied 
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after two different modes of HT. The purpose of this study was to find out what would be 
a better strategy to apply HT and achieve the ideal therapeutic outcome.  
It has been reported by Madamanchi’s group that ROS can up-regulate HSP70 protein 
levels through the activation of binding of signal transducers and activators of 
transcription (STATs) to the HSP70 promoters in vascular smooth muscle cells (VSMCs) 
(105). This group exposed VSMCs to H2O2 and found that the cytoplasmic janus tyrosine 
kinase 2 (JAK2)/STAT pathway can up-regulate HSP70 and minimize oxidative stress 
effects on the cells.  The inhibition of HSP70 expression under laser/Dye/NP HT 
probably means no enhancement of ROS production within the cells. Our ROS detection 
experiments support this hypothesis, showing that no significant ROS was produced 
inside the cells after laser/Dye/NP HT as compared to controls. However, when incubator 
HT was used to mimic conditions more similar to whole body HT, we observed 
significant intracellular ROS production. This result is consistent with Moon et al. 
reporting that ROS was activated when a slow waterbath HT was applied to cells. HT can 
activate the ERK pathway and increase NADPH oxidase activity, which leads to the 
production of ROS (150). Based on our results, it seems that the application of rapid 
laser/Dye/NP HT to cells will not induce an increase of ROS. However, the specific 
mechanism of ROS abolishment within cells after laser/Dye/NP HT has to be further 
studied. 
Since there is no activation of ROS production in laser/Dye/NP HT treatment, we did not 
observe enhanced HIF-1 expression either. However, HIF-1 up-regulation was observed 
in slow and longer term HT, probably because ROS production was activated in the 
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heating process. Other groups have also suggested that the presence of ROS is able to up-
regulate HIF-1 expression (99, 151). HIF-1 is very important as a therapeutic target 
(152). Though traditional HT with slow and long-term heating appears beneficial as an 
adjuvant therapy for radiotherapy and chemotherapy since it can hinder DNA damage 
repair mechanisms and increase drug delivery (153, 154), this heating modality is also 
able to induce up-regulation of HIF-1, and the overexpression of HIF-1 could 
compromise the therapeutic effect by increasing drug resistance through up-regulation of 
p-glycoprotein, and by reducing cancer cells drug senescence (155, 156). Our results 
showed that VEGF secretion was also elevated along with the up-regulation of HIF-1, 
which could potentially result in enhanced tumor angiogenesis.  
The combination of HT and other therapies could elevate the HIF-1 expression to an even 
higher extent than just a single therapy, which could alter tumor cell behavior and make 
cells more aggressive. Therefore, it is important to review the possible molecular effects 
of HT in considering its application as an adjuvant therapy, since other groups have 
reported that HIF-1 can also be up-regulated by radiotherapy and chemotherapy (157-
159). Based on our study, IR820-PGMD NPs could be used for HT applications without 
inducing the adverse effects of HIF-1. The HT therapeutic effect would be determined 
more by the temperature and heating rate and perhaps less on the total thermal dose. By 
using laser/Dye/NP HT, we did not observe enhancement of HIF-1 and VEGF 
expression, but an improved therapeutic outcome was still achieved compared to 
incubator HT. Despite these promising results for laser/Dye/NP HT, further studies 
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should be performed to determine treatment parameters, such as how to efficiently 
deliver these NPs and the timing for HT treatment relative to the chemotherapy. 
5.6.In vivo studies 
The nanoparticles we synthesized had a size around 100 nm diameter, which is 
considered as an optimal size for particles and could possibility prolong the blood 
circulation compared to larger or smaller particle sizes according to literatures reports 
(127) (160). Therefore, it seems that our NPs should have an increased circulation time 
profile as compared to their drug’s free form. In vivo imaging studies were done in 
healthy mice. The mice imaging showed that NPs formulation enhanced IR820 
fluorescence intensity as compared to free IR820 after 24 hours (P< 0.05 for in vivo 
imaging studies). This is consistent with the literature reporting that nanoformulation or 
liposomes can result in improved plasma circulation time and protect the loading agent 
from degradation, which probably leads to the enhanced fluorescence intensity as 
compared to free form (127, 161). 
Our previous in vitro fluorescence intensity studies showed that the NPs resulted in about 
8% fluorescence intensity decrease as compared to free IR820 at the same IR820 
concentration, which may be due to the increased scattering within NPs. We have 
observed similar phenomenon in our previous study of covalent IR820-PEG diamine 
nanoconjugates (162). However, the stability of IR820 was enhanced as compared to free 
IR820 as can be seen in Table 11. Our pharmacokinetics study showed that plasma has 
significantly higher IR820 concentration in NPs form than free IR820 24h after injection. 
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Based on available literature reports, nanoformulations also seem to result in improved 
pharmacokinetic profiles, in many cases as a result of their size and surface properties, 
ability to stabilize encapsulated drugs/dyes, and reduced liver metabolism and renal 
clearance (127, 161). In addition, our biodistribution study showed that kidney IR820 dye 
content was lower in NPs form than free IR820, and the difference between DOX-IR820-
PGMD NPs and free IR820 is significant, which means less IR820 was excreted through 
the renal system when encapsulated in the NPs. When a one-compartment model was 
used to study the physiology parameters of free IR820 and IR820 encapsulated NPs (both 
DOX-IR820-PGMD NPs and IR820-PGMD NPs), the IR820 encapsulated NPs resulted 
in much longer elimination half-lives, longer mean plasma residence time, larger overall 
exposure as indicated by AUC, and slower clearance rate compared to free IR820. The 
increased IR820 plasma half-life and prolonged circulation time in NPs formulation may 
present an advantage over the free form by stabilizing the dye and allowing longer image 
collection periods in imaging studies. Additionally, a widened therapeutic window may 
be available when providing HT as an adjuvant therapy, thanks to prolonged exposure of 
tissues to IR820. Since the EPR effect is proportional to the time and amount of drug/dye 
circulating in blood (122), it would be reasonable for us to expect that NPs formulation 
should result in higher accumulation and retention of IR820 in tumors. However, further 
studies should be performed in a tumor-bearing model to support our hypothesis.  
DOX plasma half-life is enhanced when it is encapsulated in NPs. Literature reports for 
the plasma half-life of free DOX is ~2 minutes and elimination half-life of ~10.3 hours in 
mice (129). Other researchers have also observed prolonged DOX plasma half-lives in 
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different animal models when a nanoformulation, such as liposomes or NPs, was used 
(119-121). For instance, Reddy et al. reported that DOX loaded poly(butyl cyanoacrylate) 
NPs prolonged DOX half-life ~1.5 fold as compared to free DOX in rats (128). One of 
the most important DOX-loaded liposome applications in clinical cancer therapy is DOX-
HCL encapsulated in pegylated liposomes for i.v. injection (DOXIL®). The 
pharmacokinetics studies of DOXIL® in tumor-bearing mice followed a biexponential 
curve, with the first distribution half-life of 1-3 hours, and a second elimination phase 
half-life of 30-90 hours (121, 163, 164). Although DOX-IR820-PGMD NPs seem to have 
shorter plasma half-life as compared to DOXil, they could also be pegylated and thus 
longer plasma circulation time would be expected (165-167). The increased DOX plasma 
half-life could have an impact on the therapeutic efficacy, because higher overall 
exposure and prolonged exposure profiles can result in enhanced in vivo tumor uptake 
and improved therapeutic efficacy.  
5.7.Conclusions 
In this study, multifunctional PGMD NPs were successfully synthesized to be used to 
combine different therapeutic techniques such as chemotherapy and HT. The novelty of 
this study is the synthesis of a thermal and pH sensitive polymer which provides a 
controllable and predictable pharmacokinetic release profile using thermal or pH stimuli. 
This novel and adjustable delivery vehicle was loaded with the chemotherapy agent DOX 
and the imaging and HT agent IR820. The resulting NP formulations can be used to 
improve cellular uptake and cytotoxicity in the MDR cancer cell line Dx5. The 
combination of chemotherapy and HT also enhanced DOX cytotoxicity in both MES-SA 
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and Dx5 compared to single therapy alone, indicating that less DOX can be used when 
“adjuvant” cancer therapy is introduced. In vitro and in vivo studies showed that the NPs 
yield higher IR820 fluorescence intensity than free IR820 after 24 hours, allowing longer 
imaging collection times and potentially widening the window for HT applications. 
Additionally, we proved in our study that using IR820-PGMD NPs, laser/Dye/NP HT 
will not activate ROS expression and therefore would not induce HIF-1 and VEGF 
expression. This lack of activation could yield a beneficial therapeutic outcome. In vivo 
studies showed that the IR820 in NP formulation has a longer plasma half-life than free 
IR820, providing longer imaging collection times for cancer diagnostics, and potentially 
widening the window for HT applications. An increase in DOX plasma half-life was also 
observed in NPs formulation, which could possibly result in an increased exposure of 
tumor cells to the chemotherapeutic drug; coupled with the passive targeting provided by 
the enhanced permeability and retention (EPR) effect may increase tumor uptake (168). 
This could potentially lead to improvements in therapeutic efficacy. Thus, IR820-PGMD 
NPs and DOX-IR820-PGMD NPs have promising applications as theranostic agents with 
multifunctional imaging, HT and chemotherapy capabilities. This study is an extension to 
the current knowledge of delivery of in vivo imaging probe, HT and chemotherapy in 
NPs form, and we believe it will have significant impact to the application of 
nanotechnology on cancer imaging and therapy. 
5.8.Limitations and future work  
Although the PGMD NPs seem to be promising in cancer diagnostic and therapy, more 
studies have to be performed in order to confirm our hypothesis. 
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1st. The FTIR spectrum only shows that presence of functional group C=O bond, 
indicating polyester is forming in the PGMD polymer preparation, however it can not 
give any information regarding to the composition of malic acid and DDA in PGMD 
polymer. Polymer synthesis through thermal condensation method is a process called 
step-growth polymerization by connecting two molecules and resulting in loss of small 
molecules, which in our case is water. We have indirect evidence showing that malic acid 
is included in the PGMD polymer and the change of DDA to malic acid ratio from 7:3 to 
6:4 decreases the PGMD polymer Tg to between 40-41°C. However, Nuclear Magnetic 
Resonance (NMR) spectroscopy should be acquired in order to address the questions of 
PGMD polymer composition in the future work. 
2nd . For the cellular response studies after heating by two different HT modalities, the 
mechanism of inhibited ROS production after laser/Dye/NP HT is not clear and should be 
further studied to prove that the ROS production inhibition is due to the small thermal 
dose or due to the rapid thermal heating rate, or the effect of both. In terms of molecular 
biology, different inhibitors should be used to block corresponding ROS production 
pathways and to find out exactly which pathway is used by cells to suppress the ROS 
production.  
In addition, the measurement of HIF-1 and VEGF expression after different HT were 
done in cells, which might provide valuable but limited information due to the large 
difference between an in vitro and in vivo model. Therefore, in vivo model with tumor-
bearing mice should be used to further study the in vivo HIF-1 and VEGF expression.     
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3rd . Although PGMD NPs resulted in a significant enhancement of blood circulation of 
DOX and IR820 in healthy mice, more studies must be done to further improve the NPs 
delivery. Loss of NPs during the transporting to tumors in plasma circulation often 
happens due to the binding of NPs to serum proteins known as surface opsonization, 
which results in the NPs being recognized and cleared by phagocytes or marcophages 
(161, 169). Modification of NPs surface with polyethylene glycol (PEG) can improve 
plasma circulation time and enhanced tumor uptake as compared to their non-PEGylated 
counterparts (165-167), which is possibly related to the surface charge of NPs and the 
protection of PEG to reduce albumin protein binding (127, 169). These reports indicated 
that modifying the NPs surface with PEG could be promising in enhancement of NPs 
delivery. Thus, one consideration to improve the NPs delivery is to formulate PEGylated 
PGMD NPs.  
4th . Another consideration is to formulate the NPs for targeting to achieve optimal 
delivery. As discussed before in the introduction section, antibody/ligand targeted NPs 
have better accumulation efficiency than their non-counjugated counterparts. The 
therapeutic potential of nanocarriers can be further magnified by tagging them with 
appropriate ligands that selectively interact with tumor cell membrane receptors. This 
method of tagging the drug delivery vehicle with a ligand and allowing it to specifically 
sequester in the targeted tumor is an example of active targeting and could confer greater 
specificity to different types of tumors. Therefore, PGMD NPs can be surface modified to 
conjugate different ligands or antibodies to further improve the specificity to tumor sites 
and uptake into cancer cells.   
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